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Abstract 
 
Lysosomal Storage Disorders (LSDs) are a group of rare inherited metabolic diseases 
caused by the malfunction of the lysosomal system, resulting in the accumulation of 
undegraded substrates inside the lysosomes and leading to severe and progressive 
pathology. Among them is Mucolipidosis II (ML II), one of the most severe LSDs, which is 
caused by the total or near total deficiency of the GlcNAc-1-phosphotransferase, a key 
enzyme for the correct trafficking of lysosomal hydrolases to the lysosome. One of the most 
frequent ML II causal mutations is a dinucleotide deletion on exon 19 of the GNPTAB gene 
(c.3503_3504delTC), which disrupts the reading frame and prevents the production of an 
active GlcNAc-1-phosphotransferase. Despite broad understanding of the molecular causes 
behind this and other LSDs, the same progress has not been observed in the development of 
new therapies, with current treatments being mostly symptomatic and presenting several 
limitations.  
In recent years, the RNA molecule became one of the most promising targets for 
therapeutic intervention in diseases associated with genetic mutations. One strategy that has 
been developed involves the use antisense oligonucleotides (AOs) to induce the skipping of 
specific exons bearing disease causing mutations with the purpose of altering the splicing 
pattern, the mature RNA and ultimately the final protein product. This has previously been 
applied to several disorders with encouraging results but has yet to be thoroughly explored 
for the treatment of LSDs and specifically ML II. 
Acknowledging this, this project intended to design and develop an RNA-based 
therapeutic approach through the use of AOs capable of inducing the skipping of exon 19 of 
the GNPTAB gene and consequently circumvent the effects of the most common ML II 
causal mutation and ultimately ameliorate patients’ phenotype.  
An initial in silico analysis was conducted to study the effects of this therapy on the 
GNPTAB transcript and protein product to ensure it would result in an in-frame protein and 
that no important domains would be removed. The target sequence was also explored to 
select the most promising locations for AOs aimed at inducing the skipping of exon 19 and 
four molecules were designed. ML II patient fibroblasts were then transfected with the 
selected AOs at different concentrations and their GNPTAB transcripts were analyzed. All 
four molecules produced successful exon-skipping to some extent, with the best results 
observed with the AO directed at a region of exonic enhancers in the second half of the exon 
and the one targeting the 5’ splice site. These two molecules were then tested at higher 
doses and the first proved to be the most effective, generating large amounts of the transcript 
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missing exon 19 and also reducing the levels of full-length transcript at the highest 
concentrations. 
Following RNA analysis, and because this enzyme is involved in the transport of 
lysosomal hydrolases to the lysosome, we evaluated the effects of this therapeutic approach 
at biochemical level by testing the effects of the most efficient AO on the levels of activity of 
some of these enzymes inside fibroblasts. Fibroblasts were again transfected with this 
molecule and enzymatic assays were conducted to measure lysosomal enzyme activity. 
However, no significant changes were observed. Still, this is merely an indirect measurement 
of the GlcNAc-1-phosphotransferase activity and therefore it is not possible by now to affirm 
whether or not its activity was restored, at least partially, after removal of exon 19.  
Globally, this work explored the possibility of an innovative therapeutic strategy for ML 
II through the skipping of the mutation harboring exon 19 of the GNPTAB gene and 
confirmed the ability of these AOs for RNA splicing modulation. Further studies are needed 
to verify the effect of this approach on the levels of GlcNAc-1-phosphotransferase activity 
and in the amelioration of the patients’ phenotype, but these results provide the basis for 
future research regarding the treatment of this disorder through the targeting of the aberrant 
transcript and may ultimately contribute to better quality of life for ML II patients and their 
families. 
 
 
 
Keywords: Lysosomal Storage Disorders; Mucolipidosis II; GlcNAc-1-
phosphotransferase; splicing modulation; antisense oligonucleotides; exon skipping 
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Resumo 
 
As Doenças Lisossomais de Sobrecarga (DLS) são um grupo de doenças 
metabólicas hereditárias raras, crónicas e progressivas causadas por um mau 
funcionamento do sistema lisossomal, resultando na acumulação de substratos não 
degradados no interior dos lisossomas. A Mucolipidose tipo II (ML II) é uma das patologias 
mais graves deste grupo, sendo causada pela perda de atividade da GlcNAc-1-
fosfotransferase, uma enzima essencial para o correto transporte das hidrolases lisossomais 
para o lisossoma. Uma das mutações mais frequentes em doentes com ML II é a deleção de 
um dinucleótido no exão 19 do gene GNPTAB (c.3503_3504delTC) que altera a grelha de 
leitura do mRNA e impede a produção de uma GlcNAc-1-fosfotransferase ativa, 
comprometendo assim o correto transporte das enzimas lisossomais. Apesar do vasto 
conhecimento das causas moleculares responsáveis por esta e outras DLS, o mesmo 
progresso não tem sido observado no desenvolvimento de novas terapias, sendo os 
tratamentos atualmente disponíveis principalmente sintomáticos e com várias limitações.  
Nos últimos anos, a molécula de RNA tornou-se um alvo promissor para a 
intervenção terapêutica em inúmeras doenças genéticas. Uma das estratégias aplicadas 
recorre ao uso de oligonucleótidos antisense para induzir o skipping de exões contendo 
mutações patogénicas tendo por objetivo alterar o padrão de splicing, o mRNA maduro e por 
último o produto proteico. Esta abordagem foi já aplicada a outras doenças com resultados 
promissores mas ainda não foi explorada para o tratamento das DLS e mais 
especificamente da ML II. 
O objetivo principal deste projeto foi, portanto, o desenvolvimento de uma abordagem 
terapêutica envolvendo a manipulação da molécula de RNA, através do uso de 
oligonucleótidos antisense capazes de induzir o skipping do exão 19 do gene GNPTAB e, 
consequentemente, evitar os efeitos desta mutação e melhorar o fenótipo dos doentes. 
Inicialmente foi realizada uma análise in silico para estudar os efeitos desta terapia 
ao nível do transcrito e do produto proteico do gene GNPTAB para garantir que esta 
abordagem resultaria numa proteína in-frame e que não seriam removidos domínios 
relevantes. A sequência alvo foi também explorada de forma a escolher as localizações 
mais promissoras para os oligonucleótidos antisense com o objetivo de induzir o skipping do 
exão 19 e quatro moléculas foram selecionadas. Fibroblastos de doentes foram então 
transfetados com os oligonucleótidos antisense escolhidos a diferentes concentrações e os 
seus transcritos do gene GNPTAB foram analisados. Todas as quatro moléculas produziram 
o skipping do exão 19 com sucesso, sendo os melhores resultados observados com o 
14 FCUP 
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oligonucleótido dirigido à região de enhancers exónicos na segunda metade do exão e com 
a molécula direcionada ao 5’ splice site. Estes dois oligonucleótidos antisense foram então 
testados a doses mais elevadas e o primeiro provou ser o mais eficiente, originando 
quantidades elevadas de transcrito sem o exão 19 e também reduzindo os níveis do 
transcrito completo nas concentrações superiores. 
Após a análise de RNA, e uma vez que esta enzima participa na via de transporte 
das hidrolases lisossomais, foram avaliados os efeitos desta abordagem terapêutica ao nível 
bioquímico, testando os efeitos do oligonucleótido antisense mais eficiente nos níveis de 
atividade de algumas destas enzimas no interior dos fibroblastos. Os fibroblastos foram 
novamente transfetados com este oligonucleótido e foram realizados ensaios enzimáticos 
para quantificar a atividade de diversas enzimas lisossomais, não tendo sido observadas 
variações significativas. Contudo, estes ensaios são apenas uma análise indireta, não sendo 
por isso possível concluir se existe ou não recuperação, pelo menos parcial, da atividade da 
enzima GlcNAc-1-fosfotransferase após a remoção do exão 19. 
Globalmente, este trabalho explorou a possibilidade de uma estratégia terapêutica 
inovadora para ML II através do skipping do exão 19 do gene GNPTAB e confirmou a 
capacidade destes oligonucleótidos antisense para a modulação do splicing de RNA. De 
futuro, são necessários mais estudos para verificar o impacto desta abordagem nos níveis 
de atividade da GlcNAc-1-fosfotransferase e na recuperação do fenótipo dos doentes com 
esta mutação. No entanto, os resultados obtidos oferecem uma base para novos estudos 
relativos ao tratamento desta doença através da manipulação do transcrito aberrante e 
podem, em última instância, contribuir para uma melhor qualidade de vida dos doentes com 
ML II e das suas famílias. 
 
 
 
Palavras-chave: Doenças Lisossomais de Sobrecarga; Mucolipidose II; GlcNAc-1-
fosfotransferase; modulação do splicing; oligonucleótidos antisense; skipping exónico  
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1.1. Lysosomal Storage Disorders 
 
Lysosomal Storage Disorders (LSDs) are a group of rare inherited metabolic diseases 
caused by the malfunction of the lysosomal system, ultimately resulting in the accumulation 
of undegraded substrates inside the lysosomes (Filocamo & Morrone, 2011; Lieberman et 
al., 2012). As a consequence, multiple organelles and processes might be affected, such as 
signaling, vesicle trafficking, autophagy, calcium homeostasis and inflammatory response 
(Futerman & van Meer, 2004; Ballabio & Gieselmann, 2009; Platt et al., 2012), leading to cell 
death and tissue damage. These damages translate into a wide variety of clinical 
manifestations ranging from nearly asymptomatic individuals to serious and progressive 
clinical manifestations involving several organs and systems and generally resulting in death 
in the first few years of life (Platt et al., 2012). Despite being rare disorders individually, LSDs 
present a significant frequency when considered as a whole ranging from 7.6 cases per 100 
000 births in British Columbia (Applegarth et al., 2000) to 26.9 cases per 100 000 births in 
the United Arab Emirates (Al-Jasmi et al., 2012), showcasing a strong variability in incidence 
between different ethnicities and populations. In the Portuguese population, the frequency of 
these disorders is estimated to be 25 cases per 100 000 births (Pinto et al., 2004), whereas 
other European countries have revealed a LSD incidence around 12-14 cases per 100 000 
births (Poorthuis et al., 1999; Dionisi-Vici et al., 2002; Poupětová et al., 2010).  
Encompassing about 50 distinct disorders, the classification of LSDs can be quite 
challenging and complex. While it has been traditionally associated with the nature of the 
accumulated substrate, in recent years, the molecular defect responsible for each disorder 
has taken on a more important role for the grouping of these diseases, allowing for the 
inclusion of other disorders that could not be properly organized in the traditional system 
(Table 1) (Filocamo & Morrone, 2011; Boustany, 2013). Nonetheless, the traditional 
classification is still widely used for disorders such as mucopolysaccharidoses (accumulation 
of mucopolysaccharides), sphingolipidoses (accumulation of sphingolipids) and 
oligosaccharidoses (accumulation of oligosaccharides) (Ballabio & Gieselmann, 2009), and 
the measurement of accumulated substrate is still quite useful as a biomarker for both 
diagnosis and therapy follow-up in LSDs (Cox, 2005). 
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Disorder Gene Enzyme deficiency Accumulated substrates 
Sphingolipidoses    
Fabry disease GLA α-Galactosidase A Globotriasylceramide 
Farber lipogranulomatosis ASAH1 Acid ceramidase Ceramide 
Gaucher disease GBA Glucosylceramidase Glucosylceramide 
Niemann-Pick disease (A/B) SMPD1 Sphingomyelinase Sphingomyelin 
GM1-gangliosidosis (I, II and III) GLB1 GM1-β-galactosidase 
GM1 ganglioside, keratan 
sulphate, oligos, glycolipids 
GM2-gangliosidosis (Sandhoff) HEXAB β-Hexosaminidase A + B GM2 ganglioside, oligos 
GM2-gangliosidosis (Tay-Sachs) HEXA β-Hexosaminidase A 
GM2 ganglioside, 
oligos, glycolipids 
GM3-gangliosidosis ST3GAL5 GM3 synthase GM3 ganglioside 
Krabbe disease GALC β-Galactosylceramidase Galactosylceramide 
Metachromatic leucodystrophy ARSA Arylsulphatase A Sulphatides 
Sphingolipid-activator deficiency PSAP Sphingolipid activator Glycolipids 
Mucopolysaccharidoses    
MPS I (Hurler, Scheie, 
Hurler/Scheie) 
IDUA α-Iduronidase 
Dermatan sulphate, 
heparan sulphate 
MPS II (Hunter) IDS Iduronate sulphatase 
Dermatan sulphate, 
heparan sulphate 
MPS IIIA (Sanfilippo A) SGSH Heparan sulphamidase Heparan sulphate 
MPS IIIB (Sanfilippo B) NAGLU Acetyl α-glucosaminidase Heparan sulphate 
MPS IIIC (Sanfilippo C) HGSNAT 
Acetyl CoA; α-glucosaminide 
N-acetyltransferase 
Heparan sulphate 
MPS IIID (Sanfilippo D) GNS 
N-acetyl glucosamine-6-
sulphatase 
Heparan sulphate 
MPS IVA (Morquio A) GALNS 
Acetyl galactosamine-6-
sulphatase 
Keratan sulphate, 
chondroitin 6-sulphate 
MPS IVB (Morquio B) GLB1 β-Galactosidase Keratan sulphate 
MPS VI (Maroteaux–Lamy) ARSB Arylsulphatase B Dermatan sulphate 
MPS VII (Sly) GUSB β-Glucuronidase 
Dermatan sulphate, heparan 
sulphate, chondroitin 6-sulphate 
MPS IX (Natowicz) HYAL1 Hyaluronidase Hyluronan 
Oligosaccharidoses 
(glycoproteinoses) 
   
Aspartylglicosaminuria AGA Glycosylasparaginase Aspartylglucosamine 
Fucosidosis FUCA1 α-Fucosidase 
Glycoproteins, glycolipids, 
Fucoside-rich oligos 
α-mannosidosis MAN2B1 α-Mannosidase Mannose-rich oligos 
β-mannosidosis MANBA β-Mannosidase Man (β1 → 4) GlnNAc 
Schindler disease NAGA N-acetylgalactosaminidase 
Sialylated/asialoglycopeptides, 
glycolipids 
Sialidosis (mucolipidosis I) NEU1 Neuraminidase Oligos, glycopeptides 
Glycogenoses    
Glycogenosis II (Pompe) GAA α-Glucosidase Glycogen 
Lipidoses    
Wolman disease LIPA Acid lipase Cholesterol esters 
Non-enzymatic lysosomal 
protein defect 
   
GM2 gangliosidosis 
(GM2 activator deficiency) 
GM2A GM2 activator protein GM2 ganglioside, oligos 
Krabbe disease PSAP Saposin A Galactosylceramide 
Table 1 – Classification of Lysosomal Storage Disorders (LSDs). Adapted from Filocamo & Morrone, 2011; Boustany, 2013. 
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Metachromatic leucodystrophy PSAP Saposin B Sulphatides 
Gaucher disease PSAP Saposin C Glucosylceramide 
Transmembrane protein defect    
Sialic acid storage disease SLC17A5 Sialin Sialic acid 
Cystinosis CTNS Cystinosin Cystine 
Niemann-Pick type C1 NPC1 
Niemann-Pick type C1 
protein (proton-driven 
transporter) 
Cholesterol and sphingolipids 
Niemann-Pick type C2 NPC2 
Niemann-Pick type C2 
protein (proton-driven 
transporter) 
Cholesterol and sphingolipids 
Danon disease LAMP2 
Lysosome-associated 
membrane protein 2 
Cytoplasmatic debris and 
glycogen 
Mucolipidosis IV MCOLN1 Mucolipin Lipids 
Lysosomal enzyme protection 
defect 
   
Galactosialidosis CTSA 
Protective protein cathepsin 
A (PPCA) 
Sialyloligosaccharides 
Post-translational processing 
defect 
   
Multiple sulphatase deficiency SUMF1 Multiple sulphatase Sulphatides, glycolipids, GAGs1 
Trafficking defect in lysosomal 
enzymes 
   
Mucolipidosis II alpha/beta 
Mucolipidosis III alpha/beta 
GNPTAB 
GlcNAc-1-
phosphotransferase 
(α/β subunits) 
Oligos, GAGs1, lipids 
Mucolipidosis III gamma GNPTG 
GlcNAc-1-
phosphotransferase 
(γ subunit) 
Oligos, GAGs1, lipids 
Polypeptide degradation defect    
Pycnodysostosis CTSK Cathepsin K Bone proteins 
Neuronal ceroid lipofuscinoses 
(NCLs) 
   
NCL 1 PPT1 
Palmitoyl protein 
thioesterase (PPT1) 
Lipofuscin, saposins A and D 
NCL 2 TPP1 
Tripeptidyl peptidase 1 
(TPP1) 
Lipofuscin, subunit c of ATP 
synthase 
NCL 3 CLN3 
CLN3, lysosomal 
transmembrane protein 
Lipofuscin, subunit c of ATP 
synthase 
NCL 4 DNAJC5 
DnaJ homologue subfamily 
C member 5 
Lipofuscin, subunit c of ATP 
synthase 
NCL 5 CLN5 
CLN5, soluble lysosomal 
protein 
Lipofuscin, subunit c of ATP 
synthase 
NCL 6 CLN6 
CLN6, transmembrane 
protein of ER 
Lipofuscin, subunit c of ATP 
synthase 
NCL 7 MFSD8 
CLN7, lysosomal chloride 
channel 
Lipofuscin, subunit c of ATP 
synthase 
NCL 8 CLN8 
CLN8, transmembrane 
protein of ER 
Lipofuscin, subunit c of ATP 
synthase 
NCL 10 CTSD Cathepsin D Lipofuscin, saposins A and D 
NCL 11 GRN Progranulin ─ 
NCL 12 ATP13A2 P type ATPase ─ 
NCL 13 CTSF Cathepsin F ─ 
NCL 14 KCTD7 
Potassium channel 
tetramerization domain-
containing protein 7 
─ 
1 GAGs: Glycosaminoglicans  
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1.1.1. Mucolipidosis II 
 
Like many other glycoproteins, soluble lysosomal proteins are synthesized in the 
endoplasmic reticulum and are co-translationally glycosylated on certain asparagine 
residues. After synthesis and glycosylation, lysosomal enzymes enter the Golgi apparatus 
where a mannose 6-phosphate (M6P) marker is added to the peptide, allowing for its binding 
to the M6P receptors in the Golgi and subsequent targeting to the lysosomes (Kornfeld, 
1986). This modification is performed by two Golgi enzymes in sequential action. Initially, the 
enzyme N-acetylglucosamine-1-phosphotransferase (GlcNAc-1-phosphotransferase) 
transfers N-acetylglucosamine-1-phosphate (GlcNAc-1-P) to mannose residues in the 
peptide, after which a second enzyme, N-acetylglucosamine-1-phosphodiester α-N-
acetylglucosaminidase (also known as “uncovering enzyme”) removes the GlcNAc residue to 
expose the M6P modifications, which can then be recognized by M6P receptors (Figure 1) 
(Qian et al., 2010). 
 
 
 
Figure 1 – Newly synthesized lysosomal enzymes are transported from the endoplasmic reticulum 
into the Golgi apparatus where a mannose-6-phosphate (M6P) marker is added through the action of 
two enzymes: GlcNAc-1-phosphotransferase transfers GlcNAc-1-P to mannose residues of the 
peptide, while N-acetylglucosamine-1-phosphodiester α-N-acetylglucosaminidase (“uncovering 
enzyme”) removes the GlcNAc residue to expose the M6P modifications. Subsequently, the 
lysosomal enzymes bind to M6P receptors and are targeted to the lysosomes. Adapted from 
Coutinho et al., 2012. 
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Total or near-total deficiency of GlcNAc-1-phosphotransferase impairs the formation 
of this M6P marker, resulting in the nearly complete absence of lysosomal targeting in many 
cell types and tissues and the secretion of most lysosomal enzymes (Braulke et al., 2008). 
This defect is clinically recognized as mucolipidosis II (ML II or I-cell disease; MIM# 252500), 
an autosomal recessive disease often resulting in death in the first decade of life (Reitman et 
al., 1981b). Another type of mucolipidosis, mucolipidosis III (ML III or pseudo-Hurler 
polydystrophy; MIM# 252600), is a milder disease in which GlcNAc-1-phosphotransferase 
activity is reduced rather than absent (Honey et al., 1982). 
The GlcNAc-1-phosphotransferase enzyme is an hexameric complex composed of 
two α, two β and two γ subunits, with α and β exerting the catalytic activity of the enzyme, 
whereas γ chains facilitate the folding of the catalytic subunits and maintain them in the right 
configuration, while also regulating their activity (Figure 2) (Bao et al., 1996; Coutinho et al.,  
2012). 
 
The α and β subunits are encoded by GNPTAB, a gene located on chromosome 12, 
composed of 21 exons (Tiede et al., 2005), while the γ subunits are encoded by GNPTG, a 
gene located on chromosome 16, composed of 11 exons (Raas-Rothschild et al., 2000). 
Defects in GNPTAB result in ML II alpha/beta and ML III alpha/beta whereas mutations in 
GNPTG have only been found in ML III gamma patients. Being encoded by the same gene, 
the α and β subunits are synthesized as a single precursor protein in the endoplasmic 
reticulum, which is later cleaved in the Golgi apparatus by the site-1 protease to produce 
mature α and β subunits (Marschner et al., 2011; De Pace et al., 2013). Transport of the α/β-
precursor protein to the Golgi depends on the presence of two sorting motifs in the protein 
Figure 2 – Schematic representation of the GlcNAc-1-phosphotransferase. The 
enzyme is composed of two α subunits (blue), two β subunits (green) and two γ 
subunits (red). α and β subunits are responsible for the catalytic activity of the 
enzyme, while the γ subunits appear to facilitate and increase their action. 
Adapted from Pohl et al., 2011. 
38 FCUP 
Development of an antisense-mediated exon skipping therapeutic strategy for Mucolipidosis II 
 
 
sequence: an N-terminal dileucine motif and a C-terminal dibasic arginine/isoleucine/arginine 
(RIR) motif (Figure 3A) (Franke et al., 2013). The absence of one or both of these domains 
inhibits the exit of the α/β-precursor from the endoplasmic reticulum and its subsequent 
cleavage, preventing the formation of mature α and β subunits and therefore impairing 
GlcNAc-1-phosphotransferase activity. 
 
To date 142 pathogenic mutations in GNPTAB that cause ML II and ML III alpha/beta 
are listed in The Human Gene Mutation Database (Stenson et al., 2017). Almost all ML II 
patients have nonsense, frameshift, or splice-site mutations in GNPTAB, and these 
mutations are usually associated with a more severe clinical course. Conversely, ML III 
alpha/beta patients carry missense mutations or at least one hypomorphic allele that is not 
associated with a complete loss of functionality and the clinical signs and symptoms of ML III 
alpha/beta patients are milder and more slowly progressive than in ML II (Braulke et al., 
2013). Among these multiple mutations described in the GNPTAB gene, the two-nucleotide 
deletion c.3503_3504delTC on exon 19 is considered the most common among ML II 
patients, having been previously studied by our research group (Encarnação et al., 2009; 
Coutinho et al., 2011). Since it involves the deletion of two nucleotides, this mutation causes 
a frameshift in the transcript, leading to an altered amino acid sequence, as well as to a 
premature stop codon (Plante et al., 2008). The synthesized α/β-precursor peptide lacks the 
C-terminal domain, preventing its exit from the endoplasmic reticulum and subsequent 
cleavage into mature α and β subunits (Figure 3B) (De Pace et al., 2013). This impairs the 
A 
B 
Figure 3 – Motifs and domains of the α/β-precursor protein obtained from the GNPTAB gene. Blue line indicates the 
position for cleavage by the site-1 protease, while red lines indicate the location of N-terminal dileucine motif and C-
terminal arginine/isoleucine/arginine (RIR) motif, respectively. While in the wild-type protein product (A) both motifs are 
present, the C-terminal motif is missing from the mutant protein (B) due to the frameshift caused by the 
c.3503_3504delTC mutation, preventing its exit from the endoplasmic reticulum and subsequent cleavage into mature α 
and β subunits. Adapted from Franke et al., 2013; Qian et al., 2013. 
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assembly of a functional GlcNAc-1-phosphotransferase enzyme and consequently the 
formation of the M6P marker in lysosomal enzymes, which results in an almost complete 
absence of hydrolases inside the lysosomes and accumulation of undegraded substrates 
(Kudo et al., 2006). This leads to a phenotype characterized by severe psychomotor 
retardation, coarse facial features, gingival hypertrophy, short stature, hepatosplenomegaly, 
joint contractures, osteopenia and cardiopulmonary complications that usually lead to death 
in the first decade of life (De Pace et al., 2013; Velho et al., 2015). 
 
 
1.1.2. Biochemical and molecular diagnosis 
 
Since the measurement of GlcNAc-1-phosphotransferase activity usually requires a 
very laborious assay that involves the radioactive [32P]UDP-GlcNAc substrate and is only 
available in a very small number of facilities, an indirect diagnosis of ML II and ML III is more 
commonly established by the assessment of lysosomal hydrolases (Alegra et al., 2014). 
Given the impaired sorting of multiple enzymes to the lysosomes in these patients, the 
biochemical confirmation of these disorders is usually attained indirectly through the 
detection of activity of lysosomal enzymes in plasma or in cultured fibroblasts. In general, a 
ten to twentyfold increase in serum lysosomal enzymes, together with decreased 
intralysosomal levels in fibroblasts, is indicative of those disorders (Kornfeld & Sly, 2001). In 
addition, the measurement of lysosomal enzymes activity may be used in the research field 
for the evaluation of the efficiency of therapeutic approaches that are being investigated both 
in vitro and in vivo.  
Nonetheless, molecular diagnosis is essential to confirm the presence of these 
disorders, with sequencing of the GNPTAB and GNPTG coding regions detecting disease-
causing mutations in over 95% of patients. In general, ML II and ML III can be distinguished 
based on clinical criteria and disease progression but the identification of mutations in the 
GNPTAB and GNPTG genes constitutes an important tool for the correct classification of 
these disorders. In fact, the distinction between ML III alpha/beta and ML III gamma is only 
possible based on molecular diagnosis, since the two forms of ML III have the same clinical 
and biochemical characteristics. Moreover, prenatal diagnosis of at-risk pregnancies is 
dependent on prior identification of disease-causing mutations in the family (Braulke et al., 
2013). 
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1.1.3. Available treatments for LSDs and ML II 
 
Although the biochemical and molecular causes behind most LSDs have been largely 
disclosed, similar advances have not been made in the field of therapy. Currently, no 
definitive cure is available for this kind of disorders, so most available treatments focus on 
improving life expectancy and quality of life through multiple strategies (Boustany, 2013; 
Parenti et al., 2013). An obvious approach for treatment of these disorders is the restoration 
of enzyme activity, which can be achieved by different kinds of procedures. One possibility is 
hematopoietic stem cell transplantation (HSCT), where the patient’s tissues can be 
repopulated with the donor’s healthy cells, which will then produce the functional enzyme at 
normal levels and hopefully ameliorate the symptoms of the disease (Parenti et al., 2013). 
However, this sort of treatment has only proved helpful for a limited number of conditions, 
patients must be in their early childhood for this procedure to be effective, and the rate of 
associated complications and mortality is significant (Malatack et al., 2003; Cox, 2015). 
Another therapeutic approach is enzyme replacement therapy (ERT), in which a recombinant 
form of the target enzyme is administered to patients to be then taken up by the patient’s 
cells, where it is targeted to the lysosome to replace the defective enzyme and degrade the 
accumulated substrate (Parenti et al., 2013). Nonetheless, despite good results in improving 
the function of multiple organs, this form of therapy is unable to have any effect on the 
central nervous system (CNS) since the exogenous enzyme cannot cross the blood–brain 
barrier (BBB), limiting its application (Boustany, 2013; Parenti et al., 2013). Yet another 
common option for LSD treatment is substrate reduction therapy (SRT), which aims to 
reduce the production of the accumulated substrate so that patients with residual enzyme 
activity can successfully degrade it and avoid excessive storage in the lysosome (Bruni et al., 
2007). For that purpose, this therapy uses small-molecule inhibitors to target specific steps in 
the biosynthetic pathways of the accumulated substrate and block or decrease the synthesis 
of these materials. Since the drugs used here are composed of very small molecules, they 
are able to cross the BBB and successfully reach the CNS, making it a better option for 
multiple disorders that involve the CNS (Parenti et al., 2013). 
Unfortunately, in the specific case of ML II, many of these therapies are unsuitable 
given the nature of the affected enzyme and accumulation of multiple substrates inside the 
lysosomes. On one hand, ERT is not an option as the defective enzyme is not a lysosomal 
enzyme that can be internalized by the cells and targeted to the lysosome, and SRT also 
does not fit this disorder since various substrates are accumulated within the lysosomes due 
to a near total absence of hydrolytic enzymes in this organelle. Furthermore, although HSCT 
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has been reported in the past for the treatment of ML II (Grewal et al., 2003), no benefits 
were observed in the musculoskeletal system and the survival rate is quite low (Lund et al., 
2014).  
Acknowledging this, some innovative therapeutic approaches have been developed in 
recent years, including the usage of pharmacological chaperones that promote the correct 
folding and trafficking of defective proteins (Sawkar et al., 2006), the combination of these 
chaperones with ERT (Boustany, 2013), the induction of ribosomal read-through of nonsense 
mutations allowing for the production of a full-length protein (Parenti et al., 2013), and even 
gene therapy through the introduction of the correct gene sequence into the affected cells so 
that the functional enzyme can be produced (Bruni et al., 2007; Cox, 2015). Considering the 
impact of these disorders in both patients and families, there is an urgent need to invest in 
the development of new therapeutic strategies for their treatment in order to ameliorate the 
disease phenotype, offering to patients the best possible clinical outcome together with 
minimal side effects and improved quality of life. 
 
 
1.2. Splicing therapies 
 
1.2.1. Splicing reaction 
 
The expression of eukaryotic genes requires a sequential series of finely regulated 
steps, amongst which one of the most important is splicing. In the process of splicing, non-
coding introns are removed from the precursor messenger RNA (pre-mRNA) molecule and 
the coding sequences (exons) are joined together to produce the mature mRNA that will be 
exported to the cytoplasm and translated into protein (Matera & Wang, 2014). The splicing 
reaction is carried out by the spliceosome, a large RNA and protein complex, constituted by 
five small ribonucleoprotein complexes (snRNPs) and more than a hundred proteins (Matera 
& Wang, 2014). The first step of spliceosome assembly is the recognition of the 5’ splice site 
(ss) by the U1 snRNP, followed by the binding of splicing factor 1 (SF1) to the branch point 
and of the U2 auxiliary factor heterodimer (U2AF 65/35) to the polypyrimidine tract (Py) and 
3’ss, originating the E complex (Chen & Manley, 2009; De Conti et al., 2013). SF1 is then 
replaced by the U2 snRNP at the branch point, originating the A complex and allowing for the 
interaction between U1 snRNP and U2 snRNP across the exon (Chen & Manley, 2009; 
Matera & Wang, 2014). Afterwards, the U4, U5 and U6 snRNPs are recruited as a 
preassembled complex, leading to the formation of the B complex. The interaction between 
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U4 and U6 is then disrupted and the U6 snRNP base pairs with the 5’ss, displacing U1 
snRNP from its initial location and releasing it from the complex, along with the U4 snRNP 
(Will & Lührmann, 2011). At the same time, U6 snRNP also interacts extensively with U2 
snRNP, bringing the 5’ss and the branch point into close proximity and allowing for the first 
step of splicing to take place, which originates the C complex containing the free upstream 
exon and the intron-exon lariat intermediate (Matera & Wang, 2014). This complex 
undergoes further ATP-dependent conformational changes and completes the second step 
of the splicing reaction, releasing the lariat intron and joining the coding exons to form the 
mature mRNA, while U2, U5 and U6 snRNPs are also released from the complex and 
recycled for future splicing reactions (Figure 4) (Matera & Wang, 2014). 
 
 
1.2.2. Splicing signals and regulatory elements 
 
Although the spliceosome orchestrates pre-mRNA processing with great complexity 
and fidelity, this is a fairly flexible mechanism under strong regulation by both cis-acting and 
trans-acting elements. The 5’ and 3’ splice sites and the branch point are present in every 
Figure 4 – Schematic representation of the spliceosome assembly and splicing process. U1 snRNP initially binds to the 
5’ splice site (ss), while the splicing factor 1 (SF1) binds to the branch point (A) and the U2 auxiliary factor heterodimer 
(U2AF 65/35) binds to the 3’ ss and polypyrimidine tract (Py). Next, U2 snRNP binds to the branch point, excluding SF1 
from the complex and interacts with U1 snRNP. U5, U4 and U6 snRNPs are then recruited as a preassembled complex 
with U6 snRNP binding to the 5’ss and interacting closely with U2 snRNP, displacing the U1 and U4 snRNPs and 
bringing the 5’ss and the branch point into close proximity for the first step of the splicing reaction. The spliceosome 
complex undergoes further conformational changes, resulting in the release of the intronic sequence and junction of the 
two exons, to produce the mature mRNA. Adapted from Chen et al., 2009; Will & Lührmann, 2011; Kornblihtt et al., 
2013. 
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intron and therefore are known as core splicing signals (Wang & Burge, 2008). The 5’ss 
(donor site) is located at the upstream intron junction with the consensus sequence 
AGGURAGU, while the 3’ss (acceptor site) includes the 10-20 nucleotide long polypyrimidine 
tract and the dinucleotide AG at the downstream intron junction (Reed, 1996; Faustino & 
Cooper, 2003; Kornblihtt et al., 2013). The branch point is located 20-40 nucleotides 
upstream the 3’ss and consists of a highly conserved adenosine surrounded by a poorly 
conserved sequence of 7 nucleotides (Figure 5) (Reed, 1996; Kornblihtt et al., 2013). 
 
 
 
 
 
 
 
 
 
 
Although this core splicing signals are highly conserved in less complex organisms, 
they tend to be less conserved in higher eukaryotes (Warf & Berglund, 2010), thus requiring 
the involvement of other cis-elements for the correct recognition of introns and exons. These 
elements can be enhancers or silencers depending on their role in promoting or inhibiting 
exon inclusion, respectively, and can also be divided into intronic or exonic elements 
depending on their location. As such, intronic splicing enhancers (ISEs) and exonic splicing 
enhancers (ESEs) favor the inclusion of the exon into the mature mRNA molecule, while 
intronic splicing silencers (ISSs) and exonic splicing silencers (ESSs) repress exon inclusion 
(Figure 6) (De Conti et al., 2013). 
 
 
Figure 5 – Core splicing signals within the pre-mRNA molecule. The consensus sequences are as indicated with N 
being any nucleotide, R being a purine and Y being a pyrimidine. The 5’ splice site (ss) is located at the upstream 
intron junction with the consensus sequence AGGURAGU, while the 3’ss includes the polypyrimidine tract and the 
dinucleotide AG at the downstream intron junction. The branch point is defined by a highly conserved adenosine 
surrounded by seven poorly conserved nucleotides located 20-40 nucleotides upstream of the 3’ss. Adapted from 
Matlin et al., 2005; Kornblihtt et al., 2013. 
Figure 6 – Cis-acting splicing regulatory elements. Intronic splicing silencers (ISSs) and exonic splicing 
silencers (ESSs) repress the inclusion of the target exon in the mature mRNA, while intronic splicing 
enhancers (ISEs) and exonic splicing enhancers (ESEs) promote exon inclusion. Adapted from Matlin et 
al., 2005; Kornblihtt et al., 2013. 
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ESEs are for the most part recognized by serine/arginine (SR) proteins, which also 
contain domains for protein-protein interaction (Wang & Burge, 2008; De Conti et al., 2013), 
while proteins associated with ISEs are still poorly characterized. In the case of silencer 
elements, ESSs and ISSs are recognized by members of the heterogeneous nuclear 
ribonucleoprotein (hnRNP) protein family, which act through different mechanisms, such as 
blocking interactions between spliceosome elements (Spellman & Smith, 2006) or promoting 
inhibitory RNA structures (Fisette et al., 2010). Nonetheless, the activity of a certain 
regulatory element often depends on its location within the pre-mRNA, a property called 
“context dependence” (Wang & Burge, 2008). Additionally, splicing can be affected in 
multiple aspects by other factors, such as phosphorylation, subcellular localization, ratio 
between SR proteins and hnRNPs and RNA secondary structure (Matlin et al., 2005; Jensen 
et al., 2009; Warf & Berglund, 2010). 
 
 
1.2.3. Alternative Splicing  
 
Aside from the so-called constitutive splicing process, alternative splicing (AS) also 
occurs, with some sequences altering between inclusion and exclusion into the mature 
mRNA (Faustino & Cooper, 2003; Revil et al., 2010; Liu et al., 2012). Since most AS events 
occur in the coding sequences of the mRNA transcript, they have consequences in the 
sequence of encoded proteins, affecting their structure and biological activity on multiple 
levels (Stamm et al., 2005). In that sense, AS events can be classified into five basic groups: 
cassette exons, mutually exclusive exons, alternative 5’ splice sites, alternative 3’ splice sites 
and intron retention (Figure 7A to Figure 7E) (Gamazon & Stranger, 2014; Sveen et al., 
2016). Aside from these main types of AS, alternative transcripts can also arise from the 
usage of alternative promoters or alternative polyadenylation, which provide additional 
variability to mRNAs produced from a single gene (Figure 7F and Figure 7G) (Matlin et al., 
2005; Roy et al., 2013). Furthermore, AS can also affect gene expression through removal or 
addition of regulatory elements that control mRNA stability, localization and translation 
(Faustino & Cooper, 2003). Lastly, not only the sequence of the transcript can be altered, but 
also its abundance, which is associated with several development processes, such as sex 
determination, tissue-differentiation and muscle contraction (Black, 2003), as well as with a 
number of different diseases (Love et al., 2015; Sveen et al., 2016). 
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1.3. Antisense Oligonucleotides 
 
In the last two decades, many approaches have been explored in the field of RNA-
based therapeutics in order to manipulate splicing of pre-mRNA or promote degradation of a 
mutant mRNA. Concerning the modulation of splicing, although multiple methods can be 
employed, the vast majority involves the usage of antisense oligonucleotides (AOs). AOs are 
short synthetic oligonucleotides that bind to target RNAs through standard Watson-Crick 
base pairing (Bennett & Swayze, 2010). AOs can act via different mechanisms and, in the 
case of splicing modulation, they are designed to target splice sites or splicing regulatory 
elements, blocking the binding of splicing factors and spliceosome components, which 
results in alterations in the splicing pattern and the final protein product (Hammond & Wood, 
2011; Evers et al., 2015). 
 
 
1.3.1. Chemical modifications: three generations of oligonucleotides 
 
Initially, AOs were just synthetic unmodified DNA or RNA, which despite delivering 
some promising results, would prove to be quite ineffective in biological systems due to their 
susceptibility to degradation by nucleases, poor affinity for their target mRNA, multiple off-
Figure 7 – Representation of the most common forms of alternative splicing. A: cassette exon; B: 
mutually exclusive exons; C: alternative 5' splice sites; D: alternative 3' splice sites; E: intron 
retention; F: alternative promoters; G: alternative polyadenylation. Adapted from Matlin et al., 2005. 
A B 
C D 
E F 
G 
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target effects, inability to cross the cell membrane given their negative charge and weak 
binding to plasma proteins leading to rapid clearance by the kidney (Bennett & Swayze, 
2010; Evers et al., 2015; Chery & Näär, 2016). Therefore, chemical modifications were made 
in the oligonucleotides, generating three categories of AOs, commonly known as 
generations, with different chemical and pharmacological properties (Figure 8). The first 
generation of oligonucleotides is characterized by alterations in the backbone, the most 
common being the phosphorothioate (PS) backbone, accomplished by the replacement of 
one of the non-bridging oxygen atoms with a sulphur atom. This modification allows for an 
improved nuclease resistance, as well as strong binding to plasma proteins, reducing renal 
clearance, but still presents poor binding affinity, low specificity and poor cellular uptake 
(Chan et al., 2006; Bennett & Swayze, 2010; Evers et al., 2015; Chery & Näär, 2016). 
Despite these disadvantages, PS oligonucleotides are still the most commonly used AOs and 
were the first antisense-based drug approved for clinical use in 1998 with fomivirsen 
(Vitravene®) (Roehr, 1998). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In order to surpass the downsides of the first generation oligonucleotides, a second 
generation was developed through modifications at the 2’ position of the ribose (Figure 8). 
The most widely studied second generation AOs are 2’-O-methyl (2’-OMe) and 2’-O-
methoxyethyl (2’-MOE), which present higher nuclease resistance and higher affinity for the 
target RNA, while also reducing non-specific protein binding and toxicity (Chan et al., 2006; 
Figure 8 – Chemical modifications of antisense oligonucleotides. First generation oligonucleotides are characterized by 
a phosphorothioate (PS) backbone, obtained through the replacement of an oxygen atom with a sulfur atom. Second 
generation oligonucleotides contain a methyl or methoxyethyl group attached to 2’ position of the ribose. Finally, third 
generation oligonucleotides carry modifications in the furanose ring structure. Adapted from Chan et al., 2006. 
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Bennett & Swayze, 2010; Chery & Näär, 2016). These second generation AOs, however, do 
not support RNase H-mediated cleavage of the target mRNA, which impairs their usage for 
purposes of gene downregulation (Chan et al., 2006; Bennett & Swayze, 2010). To minimize 
this limitation, a chimeric ‘gapmer’ AO was developed with a central ‘gap’ region of 
approximately 10 PS-modified nucleotides flanked on both sides by ‘wings’ composed of five 
2’-modified nucleotides. This allows for the binding of RNase H in the central gap region to 
promote cleavage and target degradation, while the external ‘wings’ provide higher nuclease 
resistance and higher target affinity (Chan et al., 2006; Bennett & Swayze, 2010). So far, only 
one second generation oligonucleotide drug – mipomersen (Kynamro®) – has been 
approved for clinical use in the treatment of familial hypercholesterolemia (Crooke & Geary, 
2013; Chery & Näär, 2016), while other second generation drugs are currently under clinical 
trials for transthyretin (TTR) amyloid cardiomyopathy, type 2 Diabetes and gastrointestinal 
autoimmune disease (Chery & Näär, 2016). 
Finally, the third generation of oligonucleotides is characterized by modifications of 
the furanose ring of the nucleotide, with the most common being peptide nucleic acids 
(PNAs), locked nucleic acids (LNAs) and phosphoroamidate morpholino oligomers (PMOs) 
(Figure 8) (Chan et al., 2006). These modifications further increase nuclease and protease 
resistance, target affinity, specificity and in vivo stability of antisense drugs, while also 
reducing non-specific interactions with proteins (Dias & Stein, 2002; Chan et al., 2006; 
Bennett & Swayze, 2010; Evers et al., 2015). Nevertheless, PNAs and PMOs present poor 
cellular uptake, low water solubility and are rapidly cleared from the blood due to their 
uncharged nature (Bennett & Swayze, 2010; Aartsma-Rus, 2012; Evers et al., 2015), 
whereas LNAs appear to generate higher toxicity than other chemical modifications, 
questioning their safety for therapeutic applications (Bennett & Swayze, 2010; Evers et al., 
2015). 
 
 
1.3.2. Oligonucleotides for splicing modulation 
 
For the purpose of splicing modulation, AOs are designed to base-pair to their target 
pre-mRNA in regions that influence splicing to ultimately alter the sequence of the protein-
coding mRNA (Havens et al., 2013). As such, second or third generation oligonucleotides are 
required in order to avoid RNase H-mediated cleavage and consequent mRNA degradation, 
which is promoted by unmodified and PS-oligonucleotides (Bauman et al., 2009). Splicing 
modulating AOs can then act through multiple mechanisms (Figure 9). 
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On one hand, AOs can be used to block cryptic splice sites in the pre-mRNA, 
redirecting the splicing machinery to the canonical splice sites and restoring correct splicing 
of the transcript (Figure 9A and Figure 9B) (Havens et al., 2013; Arechavala-Gomeza et al., 
2014). This was actually the strategy employed in the first demonstration of splicing 
modulation using antisense mechanisms for the correction of causative mutations of β-
thalassemia (Dominski & Kole, 1993), and later of ataxia-telangiectasia (Du et al., 2007), 
Niemann-Pick type C (Rodríguez-Pascau et al., 2009) and Pompe disease (Bergsma et al., 
2016), among many other disorders. A different strategy in splicing modulation is isoform 
switching, where the goal is to alter the relative amounts of alternatively spliced isoforms; it is 
usually employed when there is a disruption in the balance of normally spliced transcripts, 
originating a pathological condition (Aartsma-Rus & van Ommen, 2007; Havens et al., 2013). 
Since disruption of isoform balance is often associated with tumorigenesis and tumor 
progression, this approach has shown promise for treatment of certain cancers (Renshaw et 
al. 2004; Williams & Kole, 2006; Zammarchi et al., 2011; Rigo et al., 2012). But in addition, it 
revealed to be useful for inflammatory diseases (Karras et al., 2000; Vickers et al., 2006; 
Graziewicz et al., 2008), fronto-temporal dementia and Parkinsonism associated with 
chromosome 17 (Kalbfuss et al., 2001; Peacey et al., 2012; Rigo et al., 2012) and 
A 
B 
C 
D 
Figure 9 – Different methods of antisense-mediated splicing modulation. A: blocking of cryptic splice site within 
the intronic sequence; B: blocking of cryptic splice site within the exonic sequence; C: inclusion of alternatively 
spliced exon; D: exclusion of exon or “exon skipping”. Adapted from Hammond & Wood, 2011. 
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Hutchinson-Gilford progeria syndrome (Scaffidi & Misteli, 2005; Osorio et al., 2011). 
Moreover, AOs have also been used to promote the inclusion of exons that are normally 
excluded from the final transcript, with the targeting of the SMN2 gene in spinal muscular 
atrophy (SMA) being the most common example (Figure 9C) (Hammond & Wood, 2011; 
Douglas & Wood, 2013). In this case, the 2’-MOE oligonucleotide nusinersen (Spinraza™) has 
been subject to multiple phase 2 and phase 3 clinical trials for many years, proving to be 
both safe and effective, and was recently approved by the US FDA for treatment of mild and 
severe SMA (Chiriboga et al., 2016; Ottesen, 2017). 
Lastly, antisense technology has been employed to remove one or more exons from 
the pre-mRNA in order to eliminate a disease-causing mutation or to restore a transcript 
open reading frame (ORF), in a process known as “exon skipping” (Figure 9D). The process 
results in an internally deleted in-frame mature mRNA that will originate a truncated but 
functional protein, which can ameliorate the phenotype of multiple diseases (Hammond & 
Wood, 2011; Siva et al., 2014). One of the disorders amenable to be targeted with this 
strategy is Duchenne muscular dystrophy (DMD), caused by deletions or duplications in one 
or more exons of the dystrophin gene, disrupting the ORF and leading to a deficit of its 
encoded protein (Arechavala-Gomeza et al., 2014). In this approach, AOs target specific 
exons to conceal them from the splicing machinery, causing them to be excluded from the 
mature transcript, which is later translated into an internally truncated but functional 
dystrophin similar to those associated with the much milder Becker muscular dystrophy (van 
Deutekom et al., 2007; Verhaart & Aartsma-Rus, 2012). The use of antisense technology as 
a treatment for DMD patients has experienced great development since its first application 
and rapidly progressed through human clinical trials (van Deutekom et al., 2007; Cirak et al., 
2011; Mendell et al., 2013), culminating in the approval of the PMO eteplirsen (EXONDYS 
51™) by the U. S. FDA in September 2016 (Aartsma-Rus & Krieg, 2017). 
 
Despite antisense technology having emerged as a promising therapeutic strategy for 
multiple disorders caused by very distinct genetic defects, it has been insufficiently explored 
for the treatment of LSDs. Still, given the heavy burden of LSDs for patients and families and 
the lack of adequate treatments in the current medical practice, research and investment in 
new forms of therapy are crucial for the improvement of their condition. In this line of thought, 
AOs directed to specific mutations responsible for these disorders represent an important 
field of investigation and the main focus of this study.  
  
  
 
 
 
 
 
 
 
 
 
 
 
Chapter 2 
Objectives 
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While current knowledge on the mutations responsible for LSDs is already quite vast, 
allowing for early diagnosis and better disease management, similar progress has not been 
achieved in the field of treatment. In the specific case of ML II, treatments are still mostly 
symptomatic and unable to prevent death in the first decade of life.  
Having as perspective to pave the way for future therapies, this project focused on 
the design and development of a specific RNA-based therapeutic strategy for the correction 
of the c.3503_3504delTC mutation, the most commonly found in ML II patients. The main 
purpose was the modulation of the pre-mRNA splicing pattern in order to restore the 
production of a partially functional GlcNAc-1-phosphotransferase enzyme and achieve 
positive therapeutic effects. 
 
 
More specifically, the following aims were set: 
 
- Establish stable cell lines of skin fibroblasts obtained from ML II patients 
harboring the c.3503_3504delTC mutation on exon 19 of the GNTPAB gene. 
 
- Design AOs able to promote the skipping of the mutation-containing exon 19 in 
patient fibroblasts. 
 
- Induce effectively the skipping of exon 19 in patient fibroblasts and consequently 
modulate the splicing pattern.  
 
- Increase the activity of GlcNAc-1-phosphotransferase in patient fibroblasts, 
reducing the excretion of lysosomal enzymes and increasing their levels inside 
the lysosome. 
 
- Contribute to a better global understanding of RNA therapies and splicing 
modulation in LSDs, consequently helping to reduce the current void in this kind 
of treatment for these disorders. 
 
 
 
  
  
 
  
 
 
 
 
 
 
 
 
 
 
 
Chapter 3 
Materials and Methods 
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3.1 Bioinformatical analysis  
 
A bioinformatical analysis was conducted on exon 19 of the GNPTAB gene (harboring 
the mutation), as well as on flanking intronic regions from introns 18 and 19 and final protein 
product. It was performed to assess whether an exon skipping strategy could be applied to 
this protein without significantly affecting its activity and also to select the most appropriate 
sequence to be targeted by oligonucleotides with the purpose of inducing the skipping on 
exon 19. For this analysis, all nucleotide and peptidic sequences were obtained from the 
Ensembl database (http://www.ensembl.org/) (Yates et al., 2016) and the ExPASy Translate 
Tool (http://web.expasy.org/translate/) (Artimo et al., 2012) was used for the translation of 
nucleotide sequences into amino acid sequences. 
 
 
3.1.1. Sequence alignment of GNPTAB protein products 
In order to study whether the exclusion of exon 19 from the final GNPTAB transcript 
would result in an in-frame product and maintain the amino acid sequence encoded by the 
last two exons of the gene, the expected protein product after skipping of this target exon 
was compared with the normal protein product through the alignment of both amino acid 
sequences on Clustal Omega (https://www.ebi.ac.uk/Tools/msa/clustalo/) (Sievers et al., 
2011). This same software was also used for the alignment of amino acid sequences 
encoded by exon 19 in different animal species including birds, primates and other 
mammals, in order to assess the conservation of the amino acid sequence across different 
species which can be correlated with the presence of an important domain.  
 
 
3.1.2. Prediction of protein domains within the GNPTAB protein product 
Aside from considering the information already established in the literature, the 
presence of protein domains within the amino acid sequence encoded by exon 19 was 
further analyzed using three distinct bioinformatic tools: Pfam 30.0 (http://pfam.xfam.org/) 
(Finn et al., 2016), InterPro (https://www.ebi.ac.uk/interpro/) (Mitchell et al., 2015) and the 
UniProt database (http://www.uniprot.org/) (The Uniprot Consortium, 2015). Besides protein 
domains, the secondary structure and other important features of this protein product with 
and without exon 19 were also analyzed with these softwares, with special attention to the 
region encoded by the target exon. 
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3.1.3. Prediction of glycosylation sites within the GNPTAB protein product 
To assess the possibility of post-translational modification sites within the amino acid 
sequence encoded by exon 19, glycosylation sites were predicted using two bioinformatical 
softwares: NetNGlyc 1.0 Server (http://www.cbs.dtu.dk/services/NetNGlyc/) (Gupta et al., 
2004) and GlycoEP (http://www.imtech.res.in/raghava/glycoep/submit.html) (Chauhan et al., 
2013), which provided valuable information regarding potential N-glycosylation, O-
glycosylation and C-glycosylation sites and helped complement what had previously been 
identified in the literature. 
 
 
3.1.4. Scoring of 5’ and 3’ splice sites and prediction of enhancers within 
GNPTAB exon 19  
For the selection of possible targets for AO action, 5’ and 3’ splice sites of exon 19 
were scored according to their strength, using MaxEntScan 
(http://genes.mit.edu/burgelab/maxent/Xmaxentscan_scoreseq.html) (Yeo & Burge, 2004) 
and NNSplice: Splice Site Prediction by Neural Network 
(http://www.fruitfly.org/seq_tools/splice.html) (Reese et al., 1997). In both cases, splice sites 
received a score that reflects their probability of being selected by the splicing machinery, 
with higher scores suggesting a stronger splice site and therefore a higher likelihood of being 
chosen. 
As for the prediction of enhancer elements, the softwares ESEfinder 3.0 
(http://krainer01.cshl.edu/cgi-bin/tools/ESE3/esefinder.cgi?process=home) (Cartegni et al., 
2003; Smith et al., 2006) and RESCUE-ESE (http://genes.mit.edu/burgelab/rescue-ese/) 
(Fairbrother et al., 2002) were used. Despite the fact that these bioinformatical tools are 
specifically designed to predict exonic enhancers, 50bp of the flanking intronic sequences 
from intron 18 and 19 were also analyzed together with the sequence of exon 19 to allow for 
the identification of possible intronic enhancers in close proximity to the target exon. 
 
 
3.2. Cell culture and establishment of stable fibroblast cell 
lines 
 
Skin fibroblasts of two distinct patients with an established ML II diagnosis, both 
homozygous for the c.3503_3504delTC mutation, were obtained from the Cell Line and DNA 
Biobank from Patients Affected by Genetic Diseases (Istituto Giannina Gaslini, Genova, 
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Italy), while control cells were retrieved from healthy donors. Both control and patient cells 
were cultured in Dulbecco's Modified Eagle's Medium (DMEM) (Gibco Life Technologies, 
Carlsbad, California, USA) supplemented with 10% fetal bovine serum (FBS), 5% 
penicillin/streptomycin (PenStrep) antibiotic and 5% Fungizone® (amphotericin B), 
occasionally increasing the supplementation to 20% FBS when cells exhibited very low 
growth rates. Cultured cells were kept in T-75 culture flasks in an incubator set at the 
temperature of 37°C and 5% CO2 atmosphere, receiving regular renovation of the culture 
medium.  
When 80-90% confluence was reached, culture medium was removed from the flask, 
cells were washed with phosphate buffered saline (PBS) and trypsin was added to dissociate 
cells from the culture flask. After 5 minutes at 37°C for optimal trypsin activity, cell 
dissociation was observed with an inverted microscope and cells were sub-cultured in new 
flasks with the appropriate volume of fresh medium. To save fibroblast cells for future use, 
several samples of each were cryopreserved in the first sub-culture passages. Also, the sub-
culture procedure was conducted a minimum of three times for each cell line before initiating 
any transfection experiments. 
 
 
3.3. Confirmation of the reported mutation in patient fibroblast 
cells 
Both patient fibroblast cells were subject to molecular confirmation of the reported 
c.3503_3504delTC mutation through amplification and sequencing of the target region to 
ensure the mutation was indeed present in the cultured cells. Healthy control fibroblasts 
genomic pattern was also screened for comparison with that observed in patient cells. 
 
 
3.3.1. Extraction of genomic DNA 
Firstly, the medium in the fibroblast cells containing flasks was removed by aspiration 
and cells were washed with PBS. Trypsin was then added to promote cell dissociation from 
the flask surface followed by a short period of incubation at 37°C for optimal trypsin activity. 
After incubation, 4mL of DMEM medium were added to inactivate the enzyme and the entire 
volume was transferred to a 15mL tube for centrifugation at 1500 rpm for 5 minutes. 
Following centrifugation, the supernatant was removed and the resulting pellet was 
resuspended in 1mL of PBS and transferred to a 1.5mL tube for a second centrifugation at 
13 200 rpm for 5 minutes and supernatant removal. 
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Genomic DNA was then extracted automatically from the cell pellets using the 
BioRobot EZ1® System and the EZ1 DNA Tissue Kit (QIAGEN, Hilden, Germany) with a final 
elution volume of 200µL. Following extraction, the amount of DNA in the samples was 
quantified using NanoDrop ND-1000 Spectrophotometer (Thermo Fisher Scientific, 
Waltham, Massachusetts, USA). 
 
 
3.3.2. Amplification of exon 19 of the GNPTAB gene 
After extraction, genomic DNA was used for the amplification of exon 19 of the 
GNPTAB gene through PCR using ImmoMix™ Red (Bioline, London, UK) and two primers 
previously described by Kudo et al., 2006: CCCATAGCTAAAAGGCCATCTACC (forward) 
and GTATACACTCACCCACACACATGC (reverse). Following the manufacturer’s 
instructions, the PCR amplification was carried out using 1µL of genomic DNA, 1X 
ImmoMix™ Red reaction mix and 0,5µM of each primer. The amplification program was 
composed of an initial denaturation step at 95°C for 7 minutes, followed by 35 cycles of 
denaturation at 94°C for 45 seconds, primer annealing at 60°C for 45 seconds and DNA 
strand extension at 72°C for 90 seconds, and finished with a final extension at 72°C for 10 
minutes.  
 
 
3.3.3. Evaluation of PCR amplification by agarose gel electrophoresis 
Following amplification, products were separated through agarose gel electrophoresis 
in a 2% agarose gel stained with 5µL of ethidium bromide. Volumes of 8µL of each sample 
and 6µL of 100 bp DNA Ladder Ready to Load (Solis BioDyne, Tartu, Estonia) were loaded 
into the gel and submitted to an 115V voltage for 55 minutes. After separation, the gel was 
visualized with ultraviolet light and images were obtained using the Molecular Imager® Gel 
Doc XR+ System and Image Lab™ software (BioRad, Hercules, California, USA). 
 
 
3.3.4. Sequencing of amplification products 
After confirmation of the success of the amplification reaction through gel 
electrophoresis, the GNPTAB PCR products from healthy control and the two patients were 
purified using the illustra™ ExoStar™ 1-Step Kit (GE Healthcare Life Sciences, Chicago, 
Illinois, USA) so that they could be subsequently sequenced. Adapting the manufacturer’s 
protocol, the reactions were composed of 3µL of the amplification product and 1µL of the 
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ExoStar™ mix and were incubated at 37°C for 30 minutes for optimal enzyme activity, 
followed by 15 minutes at 80°C to inactivate the enzyme. 
Immediately after purification, the purified amplification products underwent two 
separate sequencing reactions (forward and reverse) using the BigDye Terminator v1.1 
Cycle Sequencing Kit (Applied Biosystems, Foster City, California, USA). Both reactions 
were composed of 0,5µL of the BigDye reaction mix, 0,5µL of the BigDye reaction buffer, 
0,5µL of the corresponding primer (5µM), 2µL of the purified amplification product and 6,5µL 
of sterile water to complete a final volume of 10µL. PCR conditions consisted in an initial 
denaturation step of 10 minutes at 96°C, followed by 25 cycles of denaturation at 96°C for 10 
seconds, primer annealing at 50°C for 5 seconds and strand extension at 60°C for 4 minutes. 
The sequencing products of the patient fibroblast cells  were then purified and separated 
through capillary electrophoresis in an ABI Prism 3130xl Genetic Analyzer (Applied 
Biosystems, Foster City, California, USA) and the resulting electropherograms were 
analyzed using the Chromas Lite 2.01 software (Technelysium, South Brisbance, Australia). 
Sequences were then compared with the GNPTAB reference sequence ENSG00000111670 
(retrieved from the Ensembl database) using the Clustal Omega bioinformatic tool. 
 
 
3.4. Analysis of endogenous splicing pattern in patient 
fibroblast cells 
Aside from the confirmation of the presence of the c.3503_3504delTC mutation in the 
cultured patient fibroblasts, the endogenous splicing pattern of the GNPTAB gene in these 
cells was also examined to ensure that no alterations were present prior to the modulation of 
splicing by the AOs. Once again, healthy control fibroblasts were also analyzed for 
comparison. 
 
 
3.4.1. Extraction of total RNA 
Fibroblast cell pellets were collected through a similar process to the one used for 
genomic DNA extraction described in 3.3.1. Therefore, culture medium was removed and 
cells were washed with PBS, followed by dissociation from the flask through trypsinization. 
Afterwards, cells were centrifuged and supernatant was removed to obtain a final cell pellet.  
Afterwards, total RNA was extracted from cell pellets with the GRS Total RNA Kit – 
Blood & Cultured cells (GRiSP, Porto, Portugal) with a final elution volume of 50µL. The 
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amount of RNA in the samples was then assessed using NanoDrop ND-1000 
Spectrophotometer (Thermo Fisher Scientific, Waltham, Massachusetts, USA). 
 
 
3.4.2. Synthesis of cDNA  
After RNA extraction and quantification, cDNA synthesis was carried out using the 
Ready-To-GoTM You-Prime First-Strand Beads kit (GE Healthcare Life Sciences, Chicago, 
Illinois, USA) with an initial sample volume containing 0,5µg of total RNA to which RNase-
free deionized water was added to complete a final volume of 30µL. RNA samples were then 
incubated at 65°C for 10 minutes to disrupt any RNA secondary structure and placed on ice 
for a minimum of 2 minutes afterwards. Next, the RNA samples were transferred to the bead-
containing tubes included in the kit, as well as 2µL of RNase-free deionized water and 1µL of 
oligo(dT)18 primer mix (NZY Tech, Lisbon, Portugal) at 50µM for a final volume of 33µL. After 
1 minute of room temperature incubation, the tube contents were vortexed and incubated at 
37°C for 60 minutes for the synthesis of the cDNA strand. The resultant cDNA was stored at 
-20°C until future use. 
 
 
3.4.3. Amplification of GNPTAB transcript cDNA  
After synthesis, cDNA was used for the amplification of the 21 exons of the GNPTAB 
transcript through PCR using ImmoMix™ Red (Bioline, London, UK) and the primers 
described in Table 2. The PCR reaction was carried out using 2µL of cDNA, 1X ImmoMix™ 
Red reaction mix and 0,5µM of each primer. For reactions displaying large amounts of 
unspecific products, 5% of betaine was added to the reaction corresponding to a volume of 
1,25µL, and for those with low intensity levels of the specific amplicon, the cDNA volume was 
increased to 3µL. The amplification program was composed of an initial denaturation step at 
95°C for 7 minutes, followed by 35 cycles of denaturation at 94°C for 45 seconds, primer 
annealing at the appropriate temperature for each primer set for 45 seconds and DNA strand 
extension at 72°C for 60 seconds, finishing with a final extension at 72°C for 10 minutes. 
Primer sequences and annealing temperature are described in Table 2. Following 
amplification, the success of the PCR reaction was assessed through agarose gel 
electrophoresis as described in 3.3.3 and amplification products were sequenced as detailed 
in 3.3.4. Afterwards, sequences were compared with the GNPTAB transcript reference 
sequence ENST00000299314.11 (retrieved from the Ensembl database) using Clustal 
Omega. 
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3.5. Design and synthesis of antisense oligonucleotides for 
the skipping of GNPTAB exon 19 
 
For the design and selection of the most promising AOs, we followed the guidelines 
and parameters previously described by Aartsma-Rus (Aartsma-Rus, 2012). Secondary 
structure of the target exon and flanking intronic regions was assessed using the mfold 
software (http://unafold.rna.albany.edu/?q=mfold) (Zuker, 2003). From the most stable 
structures obtained here, partially open and partially closed regions were selected for further 
analysis as these are the most appropriate locations for AO binding. Next, this information 
regarding the secondary structure of the transcript was combined with the data previously 
collected from ESEfinder 3.0 software concerning the presence of enhancers along the 
sequence of exon 19 in order to select those regions where both analysis overlap, that is, the 
partially open and partially closed regions that also contain the highest/biggest number of 
predicted enhancer elements. After this process, two internal regions within exon 19, as well 
as the acceptor and donor splice sites, were selected to be the targets for AO binding. 
With the target locations established, several AOs spanning around 20 nucleotides 
were designed for each region and tested for parameters like GC percentage, which should 
be between 40% and 60%, and melting temperature (Tm), which should be above 48°C 
(Aartsma-Rus, 2012). Free energy of the AO and AO-AO complexes was calculated using 
the software RNAstructure (http://rna.urmc.rochester.edu/RNAstructureWeb/index.html) 
Primer Sequence (5’ – 3’) Exons Tannealing (°C) 
cDNA 1F AGCTGCAATGAGCGGCGC 
1-6 59 
cDNA 1R AGCAGTCCAGAGTGGGCA 
cDNA 2F CCCTTCTACCAATGTCTCAG 
5-10 55 
cDNA 2R CCTTCCCAAACATGACATCA 
cDNA 3F AAGGGCTGTCCCAGAAGTTT 
10-13 55 
cDNA 3R TTGGTCCCTCCCTTGTGTC 
cDNA 4F CAGATAACAGTGGAGGTGGA 
13 58 
cDNA 4R TGTGTAATGCTGCAGCTTTC 
cDNA 5F GCTGAAAATCACATAGGCGT 
13-18 55 
cDNA 5R CTTCTTCTCCCATGATTTCA 
cDNA 6F CCAGTAACTGACAAAATCCA 
17-21 55 
cDNA 6R ACAGGTCCATGAGCAAATTC 
Table 2 – Sequences and annealing temperatures of primers used in the cDNA amplification of 
GNPTAB gene. 
64 FCUP 
Development of an antisense-mediated exon skipping therapeutic strategy for Mucolipidosis II 
 
 
(Reuter & Mathews, 2010). Ideally, the free energy of the AO should be above -4, while the 
free energy of the AO-AO complexes should be above -15 (Aartsma-Rus, 2012) and the AOs 
failing these numbers were discarded. Using the same software, the free energy of the exon 
and the free energy of the AO-target complex were obtained, allowing for the calculation of 
the binding energy between the AO and the target sequence, which results from the following 
formula: 
 
𝐵 = ∆𝐺𝑒 −  ∆𝐺𝑡 
 
where 𝐵 is the binding energy between the AO and the target sequence, ∆𝐺𝑒 is the free 
energy of the exon and ∆𝐺𝑡 is the free energy of the AO-target complex. This binding energy 
is a measure of the strength of the annealing between the AO and its target sequence and 
should ideally be between 21 and 28 for optimal results (Aartsma-Rus, 2012). 
Finally, after narrowing the number of AO to the most promising candidates, those 
were subject to a BLAST analysis using the nucleotide BLAST tool hosted by the NCBI 
database (https://blast.ncbi.nlm.nih.gov/Blast.cgi) (Altschul et al., 1990), in order to ensure 
their uniqueness and avoid the possibility of off-target effects. Stretches of 15 or more 
homologous nucleotides should be avoided as much as possible, even in the presence of 
mismatches, as oligonucleotides with up to five mismatches have been reported to 
successfully bind to their targets and induce exon skipping (Errington et al., 2003). Although 
total uniqueness was impossible to find among the tested oligonucleotides, those with the 
least amount of BLAST hits spanning 15 or more nucleotides saw those hits analyzed 
regarding their pattern of expression according to The Human Protein Atlas project 
(http://www.proteinatlas.org/) (Pontén et al, 2008). Using this webtool, we were able to 
examine the expression of the genes with the highest levels of similarity to our 
oligonucleotides and select those AOs which affected the least amount of tissues, reducing 
the possibility of off-target effects in multiple organs. Also, oligonucleotides with strong 
similarity to genomic regions but not transcript sequences were preferred as the RNA 
structure of these antisense molecules makes them less likely to interact with the genomic 
DNA. 
At last, four AOs were selected for transfection in patient fibroblasts, targeting both 
splice sites and two internal regions containing enhancer elements as predicted by 
ESEfinder 3.0 (Figure 10 and Table 3). The selected oligonucleotides were then synthesized 
and purified by EuroGentec (Seraing, Belgium) as second generation 2’-OMe RNA 
molecules containing a full-length phosphorothioate backbone. 
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3.6. Transfection of healthy control and ML II patient 
fibroblasts with antisense oligonucleotides  
 
After selection and synthesis of the AOs and the establishment of stable cell lines 
from ML II patient fibroblasts, cells were plated and transfected with each oligonucleotide in 
order to promote the exclusion of exon 19 from the final GNPTAB transcript. Fibroblasts from 
healthy individuals were also transfected as controls. 
 
 
3.6.1. Cell counting and plating  
Cells were cultured in 6-well (10 cm2) plates at a density of 275 000 to 300 000 cells 
per well with DMEM medium supplemented with 10% FBS, 5% PenStrep and 5% 
Fungizone®. To calculate the appropriate volume of cell suspension to be plated in each well, 
cells were counted using a Neubauer chamber as seen in Figure 11. 
Name Sequence (5’ – 3’) 
Length 
(nt) 
GC content 
(%) 
Tm 
Binding 
energy 
H19A(-18+4) CUUCCUGAAAUAACAGAGAGCC 22 45.45 53 25.4 
H19A(+45+64) AGCCUUCACUGUCUGAGCAU 20 50 51.8 27.5 
H19A(+119+138) CGGUUUCGAUACUCUCUUGG 20 50 51.8 31.1 
H19D(+12-9) AGAAUUUACCAUUCCUGCAGC 21 42.86 50.5 22.2 
Exon 19 
 
Exon 19 
H19A(-18+4) 
 
H19A(-18+4) 
H19A(+45+64) 
 
H19A(+45+64) 
H19A(+119+138) 
 
H19A(+119+138) 
H19D(+12-9) 
 
H19D(+12-9) 
Figure 10 – Location of antisense oligonucleotide targets on exon 19 of the GNPTAB gene and flanking intronic 
sequences. 
Table 3 – Sequences of antisense oligonucleotides selected for transfection in ML II patient fibroblasts. Nomenclature as 
described by Mann et al., 2002. 
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A small volume of cell suspension was deposited on each side of the chamber and 
cells present in all four external quadrants of both sides of the chamber were counted in an 
inverted microscope. Considering the dimensions of the chamber (1 mm x 1 mm x 0,1 mm), 
each quadrant has a total volume of 0,1 mm3, which equals 10-4 mL and the total cell 
concentration was calculated with the following equation: 
 
𝑁 =  
∑ 𝑛
8
 𝑥 104 
 
where 𝑁 is the total number of cells per milliliter, 𝑛 is the number of cells counted in each 
quadrant of the Neubauer chamber and multiplication by 104 allows for the correction to the 
total number of cells in 1mL of cell suspension.  
After being plated with the appropriate volume of cell suspension and growth medium, 
the 6-well plates were incubated at 37°C with a 5% CO2 atmosphere for 16-18 hours prior to 
transfection.  
 
 
3.6.2. Transfection  
After reaching 80-90% confluence, patient and healthy control fibroblasts were 
transfected with the four AOs detailed in Table 3 and Figure 10, each in four different 
concentrations: 10nM, 25nM, 50nm and 100nM. Using the Lipofection method for 
transfection, the appropriate amount of each AO was initially diluted in Opti-MEM® medium to 
complete a final volume of 250µL, while 10µL of the transfection reagent Lipofectamine® 
2000 were diluted in 240µL of Opti-MEM® medium for a final volume of 250µL. After an 
Figure 11 – Example of Neubauer chamber used for cell counting. The Neubauer chamber contains two 
distinct chambers, composed of 9 quadrants, each with a volume of 0,1 mm3 or 10-4 mL. 
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incubation period of 10 minutes at room temperature, the lipofectamine solution was added 
to the oligonucleotides to form the AO-lipid complexes, completing a total of 500µL, and this 
final mix was incubated a second time for 20 minutes at room temperature. 
Meanwhile, growth medium was removed from the plate wells and fibroblast cells 
were washed with 2mL PBS before receiving 1mL of fresh antibiotic/fungizone-free DMEM 
medium. After the second incubation period was finished, the total volume of each AO-lipid 
complex mix was added dropwise to the corresponding well and cells were incubated at 
37°C with a 5% CO2 atmosphere for 5 hours. After this time period, culture medium was 
removed and 2mL of fresh DMEM medium supplemented with 10% FBS, 5% PenStrep and 
5% Fungizone® were added to the cells, which were incubated once again at 37°C, 5% CO2 
until completing a 24 hour period after transfection.  
After this initial transfection with lower concentrations, the two most effective AOs – 
H19D(+12-9), targeting the 5’ss, and H19A(+119+138), directed at ESEs within the second 
half of exon 19 – were tested at higher doses to further analyze their potential in the splicing 
modulation of the target exon. Patient and healthy control fibroblasts were once again 
transfected and five different concentrations, ranging from 100nM to 500nM, were used, with 
all transfection and culture procedures identical to those employed for the lowest 
concentrations. 
Additionally, a plasmid containing the reporter gene eGFP, which encodes for the 
enhanced green fluorescent protein, was used as a control to assess the efficacy of the 
transfection reagent through the analysis of the fluorescence observed among the 
transfected fibroblasts. In this case, 2,5µL of plasmid solution, corresponding to 2,5µg of 
DNA, were transfected with 10µl of Lipofectamine 2000 used and fluorescence was 
observed in a fluorescence microscope 24 hours after. 
 
 
3.7. Evaluation of in vitro GNPTAB gene exon 19 splicing 
pattern modulation with antisense oligonucleotides 
 
Following transfection with AOs, the splicing pattern of the GNPTAB transcript was 
once again analyzed to verify whether the oligonucleotides successfully promoted the 
exclusion of this target exon from the final mRNA product. All procedures were identical to 
those described in 3.4, with only a few adjustments regarding the collection of cell pellets, 
using 500µL of trypsin and 1mL of DMEM medium for that purpose given the small volume of 
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the plate wells. Also, for cDNA synthesis, the specific primer GNPTAB cDNA 6R from Table 
2 was used instead of the oligo(dT)18 primer mix previously chosen. After amplification, when 
a shorter fragment had been observed through gel electrophoresis, suggesting the 
successful skipping of exon 19, products were run once again on agarose gel and the shorter 
fragments were cut off for purification with the Wizard® SV Gel and PCR Clean-Up System 
(Promega, Madison, Wisconsin, USA) followed by sequencing as described before. 
 
 
3.8. Quantification of lysosomal enzyme activity in healthy 
control and ML II patient fibroblasts after splicing pattern 
modulation with antisense oligonucleotides 
 
Following the observation of successful skipping of exon 19 from the GNPTAB final 
transcript, the effectiveness of this therapeutic approach regarding the restoration of GlcNAc-
1-phosphotransferase activity was assessed indirectly through the quantification of a number 
of lysosomal enzymes. For that purpose, fibroblasts from Patient 1 were plated in four wells 
of 6-well plates and once again transfected with the H19A(+119+138) AO at the highest 
concentration tested (500nM) as described in 3.6.2. After the incubation periods of 24 and 48 
hours, cells were dissociated and collected as previously detailed, with the volume of three 
wells used for the enzyme assays, while the volume of one well was separated for RNA 
analysis. The same experiment was done with fibroblasts from healthy individuals as a 
control. Additionally, the two cell lines were treated only with Lipofectamine 2000 in order to 
account for the influence of this transfection reagent in the experiments. 
Afterwards, pellets of each experiment were diluted in 50µL Triton 0,1% and 
sonicated in order to lyse the cells and release their internal components. Samples were then 
centrifuged at 13 000rpm for 10 minutes to collect all cellular debris at the bottom of the tube 
and the amount of total protein in the supernatant was quantified with NanoDrop ND-1000 
Spectrophotometer (Thermo Fisher Scientific, Waltham, Massachusetts, USA). From here, 
the appropriate volume of each sample for a final concentration of 0,5mg/mL was transferred 
into a new 1,5mL tube, completing the final volume with sterile water. Next, the reaction 
mixture for each enzyme was prepared and incubated at 37°C, with all assays conducted in 
duplicate to ensure the reproducibility of the results. Reaction composition and incubation 
times are detailed on Table 4. 
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Enzyme 
Protein 
sample 
Substrate Incubation time 
β-glucosidasea 10µL 25µL 4-MU-β-D-glucopyranoside 10mM 2h 
α-galactosidase 10µL 50µL 4-MU-α-D-galactopyranoside 5mM 1h30 
Arylsulfatase B (ARSB) 50µL 150µL 4-MU-sulfate 10mM 1h 
β-glucuronidase 10µL 50µL 4-MU-β-D-glucuronide 4mM 45min 
β-galactosidase 10µL 50µL 4-MU-β-D-galactopyranoside 1mM 30min 
α-mannosidase 10µL 50µL 4-MU-α-D-mannopyranoside 2mM 30min 
Total hexosaminidase 10µLb 
50µL 4-MU-2-acetamido-2-deoxy-β-D-
glucopyranoside 2mM 
15min 
a 25µL of phosphate/citrate buffer pH 5,2 were also added and two different assays were conducted: one using a substrate 
solution with sodium taurocholate (T+) and a second without sodium taurocholate (T-). 
b Samples were diluted in albumin in a ratio of 10µL of sample to 30µL of albumin, and from this dilution 10µL were used for the 
assay.  
 
After incubation was completed, 1mL of glycine was added to each test tube to stop 
the enzyme reaction and 300µL of each sample were transferred to a fluorometer plate well 
for fluorescence reading using the VICTOR 2TM D fluorometer (PerkinElmer, Waltham, 
Massachusetts, USA) at the wavelengths of 355 and 460nm. Results were then compared 
between ML II patients, healthy controls and other LSD patients, as well as before and after 
AO treatment.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4 – Composition of each enzyme activity assay and respective incubation period at 37ºC. 
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4.1. Bioinformatical analysis 
 
Several bioinformatics tools for the analysis of sequence information were used to 
explore thoroughly i) exon 19 of the GNPTAB gene where is located the c.3503_3504delTC 
mutation, the target molecular defect in this study from the therapeutic perspective; ii) its 
flanking intronic regions and iii) the final protein product. 
 
 
4.1.1. Sequence alignments of GNPTAB protein products 
We first sought to compare the amino acid sequences of both full length and 
truncated protein products in order to confirm whether the skipping of an exon in the final 
transcript would originate an in frame protein product, maintaining intact the remaining amino 
acid sequence. For this purpose, the amino acid sequence of the GNPTAB transcript minus 
exon 19 was aligned with the sequence of the complete GNPTAB protein product using 
Clustal Omega software to assess whether the exclusion of this exon from the mature mRNA 
would result in an in frame protein or if instead it would alter more drastically the final protein 
product, rendering any exon skipping approach unfit for the correction of the mutation. 
Following this alignment, it was possible to confirm that the exclusion of exon 19 from the 
final GNPTAB transcript originates an internally truncated protein with a total of 1200 amino 
acids, 56 amino acids shorter than the complete protein product, but that the reading frame 
remains intact, since the amino acid sequence without the excluded region presents a 
complete match with the normal GNPTAB protein (Figure 12). Furthermore, the amino acid 
arginine encoded across exon boundaries is also maintained, despite being the most likely to 
be altered during an exon skipping strategy even if the reading frame is unaltered and the 
amino acids beyond match the original protein sequence. There are codons for arginine 
across the boundaries between exons 18 and 19, as well as between exons 19 and 20, and 
thus the amino acid remains unchanged in the truncated protein since exon 19 and exon 20 
both start with a guanine nucleotide, maintaining the AGG codon, which codes for arginine, 
even after removal of exon 19. As such, the truncated protein obtained after the skipping of 
exon 19 exhibits a complete match with the full length GNPTAB protein product, maintaining 
the reading frame and amino acid sequence but missing the 56 amino acids spanning 
positions 1146 through to 1201 encoded by the nucleotide sequence of exon 19 which has 
been removed from the final mRNA transcript. 
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After confirming this basic pre-condition to implement an exon skipping strategy, the 
amino acid sequence encoded by exon 19 was further analyzed to ensure that its absence 
would not severely impact the activity of the final protein. Firstly, amino acid sequences 
encoded by exon 19 in different animal species were compared using Clustal Omega 
software in order to assess their conservation across different taxa and obtain insights on the 
presence of important protein domains in the region. Results from this alignment, shown in 
Figure 13, reveal a great level of conservation of this sequence in different animal species, 
with most amino acids identical across all species studied and only minor discrepancies in 
some residues in mouse and zebrafish. This degree of conservation suggests the presence 
of an important domain in this region of the protein, which could represent a serious obstacle 
to the exon skipping approach for the modulation of this mutation without impairing the 
proper activity of the final protein product. Nonetheless, although important protein domains 
usually show their sequences highly conserved across species, the opposite is not always 
true, given that there are known instances of conserved amino acid sequences despite not 
containing any important domain. Therefore, further analysis was conducted to check 
whether or not the sequence encoded by exon 19 corresponded to a crucial protein region 
and consequently whether or not an exon skipping approach could be considered for exon 
19 without severely impacting the final protein product. 
 
 
 
 
 
 
 
Figure 12 – Alignment in Clustal Omega software of amino acid sequences for the full 
length GNPTAB protein product and truncated protein resulting from the skipping of 
exon 19. Due to the long size of the protein sequence, only exons 14 to 21 are shown in 
this picture. protein: full length protein product; skip19: truncated protein. 
 
Figure 13 – Alignment in Clustal Omega software of amino acid sequences encoded by exon 
19 of the GNPTAB gene in different animal species. 
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Table 5 – Protein domains 
predicted by Pfam 30.0 for the 
GNPTAB protein product. n/a – 
not applied. 
4.1.2. Prediction of protein domains within the GNPTAB protein product 
To predict the presence of important domains within the protein region of GNPTAB 
encoded by exon 19, the Pfam 30.0 database was used, revealing the presence of multiple 
protein domains with a variety of functions across the entire sequence of the GNPTAB 
protein as seen in Table 5 and Figure 14. 
 
 
 
 
 
The expected N-terminal and C-terminal transmembrane 
domains essential for the translocation of the α/β-precursor from 
the endoplasmic reticulum to the Golgi apparatus where it is later 
cleaved into the α and β subunits of GlcNAc-1-
phosphotransferase were clearly identified at both ends of the 
protein sequence (red boxes in Figure 14), while two Notch 
domains were also found to be present within the protein (dark 
blue boxes in Figure 14). Furthermore, this protein has one DNA 
methyltransferase-associated protein (DMAP) domain (yellow in 
Figure 14), and four stealth conserved regions (CR) across its 
amino acid sequence (green, red, purple and orange in Figure 
14), with CR4 (positions 1138-1194) covering almost the entire 
sequence encoded by exon 19 (1146-1201).  
 
 
 
The bioinformatic analysis with InterPro database also predicted the presence of two 
Notch domains, one DMAP domain and four stealth regions within the GNPTAB protein 
product, and confirmed that stealth CR4 encompassed the amino acid sequence encoded by 
exon 19 (Figure 15). Additionally, this software pinpointed the presence of an EF-hand 
domain responsible for calcium binding, which was not predicted by Pfam 30.0. Aside from 
these annotated domains, other matches were identified among unintegrated signatures 
(shown in grey), indicating the N-terminal and C-terminal transmembrane domains, the 
cytoplasmic and non-cytoplasmic regions, the two GlcNAc-1-phosphotransferase subunits 
and some structural information. 
Figure 14 – Protein domains predicted by Pfam 30.0 for the GNPTAB protein product. Color codes and exact positions are 
depicted in Table 5. 
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Finally, the GNPTAB protein was also analyzed in the UniProt database concerning 
protein domains, functions and secondary structure. In the case of protein domains, the 
UniProt resource provided results coincident with the two previous bioinformatic tools, 
including this protein within the stealth protein family and confirming the presence of two 
Notch domains, one DMAP domain and one EF-hand domain (Table 6). 
 
 
 
 
 
 
 
Figure 15 – Protein domains predicted by InterPro for the GNPTAB protein product. 
Table 6 – Protein domains predicted by UniProt for the GNPTAB protein product. 
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Similarly to InterPro and Pfam 30.0, UniProt also predicted both N-terminal and C-
terminal transmembrane domains, as well as their helical conformation (Table 7). 
 
 
 
 
 
Conversely, this database anticipated that GNPTAB harbors multiple metal binding 
sites for calcium (Table 8) which had not been detected by the previous tools, as well as a 
calcium binding region which had been suggested by InterPro but not Pfam 30.0 (Table 9). 
Nonetheless, none of these sites and regions is located in the amino acid sequence encoded 
by exon 19 (1146-1201). 
 
 
 
 
 
 
 
 
 
 
The UniProt database further revealed some relevant information regarding the 
secondary structure of GNPTAB, predicting several beta strands, helixes and turns, all 
between positions 138 and 280 (Figure 16 and Table 10). Once again, no remarkable 
features were detected for the region encoded by exon 19. 
 
 
 
 
 
Table 7 – Transmembrane domains predicted by UniProt for the GNPTAB protein product. 
Table 8 – Metal binding sites predicted by UniProt for the GNPTAB protein product. 
Table 9 – Calcium binding region predicted by UniProt for the GNPTAB protein product. 
Figure 16 – Secondary structure of the GNPTAB protein predicted by UniProt software. Green: beta strand; 
pink: turn; blue: helix.  
78 FCUP 
Development of an antisense-mediated exon skipping therapeutic strategy for Mucolipidosis II 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Overall, none of these three bioinformatic tools evidenced the presence of other 
important domains or relevant secondary structure features within the amino acid sequence 
encoded by exon 19, besides the CR4 stealth domain, which should be carefully studied 
given its role in the catalytic activity of the GlcNAc-1-phosphotransferase enzyme. 
 
 
4.1.3. Prediction of glycosylation sites within the GNPTAB protein product 
Lastly, the presence of glycosylation sites within the amino acid sequence encoded 
by exon 19 of the GNPTAB gene was also predicted to ensure that this modification would 
not be affected by the removal of exon 19 from the mature transcript. Glycosylation is a co-
translational and post-translational modification in which a glycan is attached to a specific 
amino acid residue within a protein, playing an important role for its structure and function 
(Moremen et al., 2012). Therefore, if glycosylation sites were present within the amino acid 
sequence encoded by exon 19, the exclusion of those sites could severely affect the 
tridimensional conformation and activity of the protein produced after skipping of exon 19. In 
that sense, three different types of glycosylation were predicted for that amino acid 
sequence: N-glycosylation, where the glycan is linked to a nitrogen atom of asparagine or 
arginine residues; O-glycosylation, where the glycan is linked to the hydroxyl oxygen of 
Table 10 – Secondary structure of the GNPTAB protein predicted by UniProt software product. 
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serine, threonine, tyrosine, hydroxylysine or hydroxyproline residues; and C-glycosylation, 
where a mannose sugar is added to a carbon of a tryptophan residue (Spiro, 2002). 
Using the software NetNGlyc 1.0 Server, N-glycosylation sites were predicted for the 
entire amino acid sequence of the GNPTAB protein product using a threshold of 0.5, 
revealing that multiple locations showcased a strong potential for this modification, with 
results reaching the 0.7 range (Table 11 and Figure 17). Nonetheless, the amino acid 
sequence encoded by exon 19 (positions 1146-1201) did not present any predicted N-
glycosylation sites, suggesting that the removal of this protein region would not influence the 
state of glycosylation of the final protein product. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 11 – N-glycosylation sites predicted by NetNGlyc 1.0 Server for 
the GNPTAB protein product. 
Figure 17 – N-glycosylation sites predicted by NetNGlyc 1.0 Server for the GNPTAB protein 
product. 
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A second software used for glycosylation predictions, GlycoEP, besides the presence 
of the more common N-glycosylation sites, also predicts the sites for O-glycosylation and C-
glycosylation, providing a broader appraisal of possible post-translational modifications within 
the GNPTAB protein. Regarding N-glycosylation sites, the predictions were similar to those 
provided by NetNGlyc 1.0, with some positions showcasing potential for glycosylation but 
none within the amino acid sequence encoded by exon 19 (positions 1146-1201), indicating 
the very low probability of glycosylation in that portion of the protein (Table 12). In the case of 
O-glycosylation sites, predictions once again showed negative scores for positions within the 
amino acid sequence encoded by exon 19, further supporting the absence of glycosylation in 
this location, while other positions outside of exon 19 presented potential for glycosylation 
(Table 13). Finally, predictions of C-glycosylation sites showed no positive scores in the 
entire GNPTAB protein sequence, indicating that this protein does not undergo this specific 
modification (results not shown).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As a whole, these bioinformatical predictions indicate that the amino acid sequence 
encoded by exon 19 of the GNPTAB gene does not contain any positions with strong 
potential for any kind of glycosylation. Therefore, its absence likely would not disrupt the 
normal pattern of this post-translational modification in the GNPTAB protein. Additionally, this 
amino acid sequence does not include other important protein domains or secondary 
structures, besides the CR4 stealth domain, which raises concerns in respect to the 
Table 12 – N-glycosylation sites predicted 
by GlycoEP for the GNPTAB protein 
product. Only positions 922-1252 are 
shown. 
 
Table 13 – O-glycosylation sites predicted 
by GlycoEP for the GNPTAB protein 
product. Only positions 1066-1250 are 
shown. 
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therapeutic strategy in mind. In fact, given that the stealth domains together form the catalytic 
activity core of the GlcNAc-1-phosphotransferase enzyme (Liu et al., 2017), the removal of 
exon 19 from the GNPTAB transcript and the consequent absence of the CR4 amino acid 
sequence from the final protein product might have a negative impact on the activity of the 
enzyme, which should be carefully investigated. Nonetheless, the remaining results are not 
unfavorable to the implementation of this exon-skipping therapeutic approach to ameliorate 
the effects of the c.3503_3504delTC mutation in the exon 19 of the GNPTAB gene, 
ultimately expecting to produce a truncated but functional enzyme with the majority of its 
essential domains and structures. 
 
 
4.1.4. Scoring of 5’ and 3’ splice sites of GNPTAB gene exon 19 
Initially, 5’ and 3’ splice sites of exon 19 were scored according to their strength to 
check whether they could be useful targets for oligonucleotides with the intent of promoting 
the skipping of the exon. For this purpose, two distinct softwares were used, MaxEntScan 
and NNSplice, producing concordant results despite utilizing different algorithms for their 
predictions. In the case of MaxEntScan, whose ideal scores are 13.59 for the 3’ss and 11.81 
for the 5’ss, the 3’ss received a final score of 9.32, while the 5’ss was scored at just 6.41, 
suggesting a lower level of strength of the donor splice site, but a strong acceptor site. 
Similarly, NNSplice scored 3’ss at 0.94 (on a scale of 0 to 1), while 5’ss was given a 0.81. 
Taken together, these results indicate a very strong acceptor site on the boundary between 
intron 18 and exon 19 of the GNPTAB gene, which is expected to be robustly recognized by 
the splicing machinery, ensuring the proper splicing of this exon. Acknowledging the 
importance of this splice site for the recognition of the exon, this location emerges as a 
promising target for AOs in exon skipping experiments, since the blocking of this 3’ss alone 
could possibly alter the recognition of the exon by the splicing machinery and induce its 
exclusion from the final transcript. 
 
 
4.1.5. Prediction of enhancers within GNPTAB gene exon 19 
Aside from splice sites, enhancers are also an important component for the correct 
functioning of the splicing reaction, promoting the inclusion of the exon under their regulation. 
Therefore, targeting these elements with AOs can also be useful for the purpose of exon 
skipping and so the exon 19 sequence of GNPTAB gene was analyzed by two bioinformatic 
tools: ESEfinder 3.0 and RESCUE-ESE. Using the software ESEfinder 3.0, enhancers were 
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predicted on the mutant variant of exon 19 of the GNPTAB gene, as well as on 50bp of each 
flanking intron, through the search for binding motifs for five human SR proteins, revealing 
the presence of multiple enhancers on various sites across the exon and the flanking intronic 
regions. Results are shown on Table 14 and Figure 18 and multiple locations have been 
identified as putative enhancers by each SR protein matrix, with SRSF2 and SRSF6 
containing the largest number of predicted enhancer binding motifs, ten and twelve, 
respectively. Among these predictions, five locations, three targeted by SRSF2 and two 
targeted by SRSF5, present a score above four, showcasing strong potential for enhancer 
activity in these sites and therefore presenting themselves as clear candidates for targeting 
by AOs for the purpose of promoting the skipping of exon 19. Furthermore, analyzing the 
graphic in Figure 18, it is possible to observe a great number of putative enhancers in the 
downstream end of exon 19 and the beginning of intron 19, suggesting this could also be a 
good location for AO targeting since multiple enhancers could be disrupted with a single AO, 
increasing the probability of excluding exon 19 from the final transcript. Finally, it is easily 
noticeable in the graphic that the highest scoring location overlaps with the 3’ss, for which a 
high score was also predicted in the MaxEntScan and NNSplice analysis concerning the two 
splice sites flanking exon 19. Taken together with previous experiments regarding exon 
skipping for the treatment of DMD, which revealed acceptor sites and the first half of the 
exon as the most efficient annealing sites for AOs (Fletcher et al., 2012), these results 
suggest that this region could be a very strong target for AOs intended to promote the 
skipping of exon 19 by simultaneously disrupting the acceptor splice site and a powerful 
splicing enhancer. 
 
 
  
 
 
 
 
 
 
 
 
 
 
Table 14 – Putative enhancers predicted by ESEfinder 3.0 for exon 19 of the GNPTAB 
gene containing the c.3503_3504delTC mutation and 50bp of the flanking introns. 
Positions start at the beginning of the input sequence and not the beginning of exon 19. 
1-50: intron 18; 51-216: exon 19; 217-266: intron 19. 
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With RESCUE-ESE, putative enhancers are predicted according to their frequency on 
exons versus introns, as well as their frequency on exons with weak splice sites versus 
exons with strong splice sites where enhancers are expected to play a more subtle role in the 
splicing reaction. Once again, analysis with RESCUE-ESE included the mutant nucleotide 
sequence of exon 19 of the GNPTAB gene, as well as 50bp of introns 18 and 19, to predict 
enhancers within the exon but also in the flanking intronic regions (Figure 19). 
 
 
 
 
 
 
 
 
 
 
Similar to ESEfinder 3.0, RESCUE-ESE also identified multiple putative enhancers 
within the input sequence, as well as some overlap between certain predicted elements. 
Moreover, the region around the acceptor site (position 50) emerges once again as the 
location with the most predicted enhancers, with the first half of the exon also showing 
multiple predictions. However, the cluster of putative enhancers located at the downstream 
  SRSF1 
  SRSF1 (IgM-BRCA1) 
  SRSF2 
  SRSF5 
  SRSF6 
Figure 18 – Graphic representation of the putative enhancers predicted by ESEfinder 3.0 for exon 19 
GNPTAB gene containing the c.3503_3504delTC mutation and 50bp of the flanking introns. Arrows 
indicate the location of the donor and acceptor splice sites. 
5’ss 3’ss 
Figure 19 – Putative enhancers predicted by RESCUE-ESE on exon 19 of the GNPTAB gene containing the c.3503_3504delTC 
mutation and 50bp of the flanking introns. Positions start at the beginning of the input sequence and not the beginning of exon 
19. 1-50: intron 18; 51-216: exon 19; 217-266: intron 19. 
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end of the exon in the ESEfinder analysis is not replicated by this software and the sequence 
and position of many predicted elements are also very distinct from those observed with 
ESEfinder. This divergence of results highlights the variability and diversity in the prediction 
of enhancer sequences when performed by different bioinformatic tools, which can only be 
validated as splicing regulatory elements after functional splicing analysis. 
Overall, the 3’ss and the downstream end of exon 19 appear to be the most 
promising targets for AOs with the purpose of inducing the skipping of this exon, given the 
high scoring of this splice site when analyzed by the bioinformatic tools selected, as well as 
the presence of numerous putative enhancers in these regions that can be targeted to alter 
the splicing pattern and promote the exclusion of exon 19 from the final mRNA transcript. 
 
 
4.2. Confirmation of the presence of the GNPTAB gene exon 
19 c.3503_3504delTC mutation in patient fibroblast cells 
 
After the establishment of stable fibroblast cell lines from two distinct ML II patients, it 
was necessary to confirm the presence of the c.3503_3504delTC mutation in the cells before 
advancing to any further experiments. For that purpose, genomic DNA was extracted from 
both patient fibroblast cells, as well as from healthy control fibroblasts and the target region 
including exon 19 of the GNPTAB gene and its flanking intronic regions was amplified 
through PCR and subsequently sequenced to search for the ML II causing mutation. 
A single pair of primers was selected, showing specific annealing to the last portion of 
intron 18 (forward) and the beginning of intron 19 (reverse), allowing the amplification of a 
final product of 436bp that included the entire sequence of exon 19 (Figure 20).  
 
Following amplification, products were separated through agarose gel electrophoresis 
with ethidium bromide staining and visualized with ultraviolet light. As seen in Figure 21, all 
samples were successfully amplified and produced a single amplicon of around 450bp, as 
expected given the primer annealing locations. Furthermore, no unspecific products or 
reverse forward 
exon 19 intron 18 intron 19 
Figure 20 – Schematic figure of primer annealing for amplification of exon 19 of the GNPTAB gene and flanking 
intronic regions. 
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contamination were detected in any of the samples, which allowed their use for subsequent 
purification and sequencing.  
 
 
 
 
 
  
 
 
 
 
 
 
Then, the amplification products of patient fibroblasts were sequenced and results 
were compared with the GNPTAB reference sequence ENSG00000111670 obtained from 
the Ensembl database using the Clustal Omega web tool. In both cases, sequence analysis 
revealed the deletion of a TC dinucleotide, in homozygosity, at positions c.3503 and c.3504. 
As such, it was possible to confirm that this deletion corresponds to the expected 
c.3503_3504delTC mutation responsible for the ML II phenotype presented by these patients 
and the most frequent pathogenic mutation associated with this disorder (Coutinho et al., 
2011). 
 
 
4.3. Analysis of GNPTAB gene exon 19 splicing pattern in 
fibroblast cells 
 
After confirming the presence of the c.3503_3504delTC mutation in exon 19 of the 
GNPTAB gene in the cultured patient fibroblast cells, it was then needed to study the 
endogenous splicing pattern of these fibroblasts before starting the splicing modulation 
experiments in order to assure that no previous disruption of the splicing process occurred in 
the cells prior to transfection with AOs and that the GNPTAB transcript was produced as 
expected. 
~450bp 
      L             B             HC            P1           P2 
Figure 21 – Agarose gel electrophoresis of PCR amplification 
of GNPTAB gene exon 19 and flanking intronic regions in 
control and patient fibroblasts. L: ladder; B: negative control 
(blank); HC: healthy control; P1: ML II Patient 1; P2: ML II 
Patient 2. 
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Viewing that, total RNA was extracted from the two patient cell lines, as well as from 
healthy control fibroblasts, and cDNA was synthesized using an oligo(dT)18 primer, therefore 
covering all the transcripts present in the samples. For the PCR reaction, six different sets of 
primers were employed, each of them directed at a specific location of the GNPTAB 
transcript and ensuring that the total coding sequence of the mRNA molecule was amplified, 
as shown schematically on Figure 22. Exons covered by each of the primer sets and 
corresponding amplicon sizes are detailed in Table 15. 
 
 
 
 
 
 
 
 
 
 
 
Following amplification, the products were separated through agarose gel 
electrophoresis with ethidium bromide staining and visualized under ultraviolet light. As 
expected, all samples revealed a band between 700bp and 750bp, confirming the success 
and specificity of the PCR reaction (Figure 23). 
 
 
Primer set Exons Amplicon size (bp) 
cDNA 1F / cDNA 1R 1-6 736 
cDNA 2F / cDNA 2R 5-10 716 
cDNA 3F / cDNA 3R 10-13 732 
cDNA 4F / cDNA 4R 13 774 
cDNA 5F / cDNA 5R 13-18 763 
cDNA 6F / cDNA 6R 17-21 734 
 exon 2 
Figure 22 – Schematic representation of annealing locations of all six primer sets for amplification of different 
fragments of the GNPTAB transcript. 
     
        
       exon 1 exon 3 exon 4 exon 5 exon 6 exon 7 exon 8 
exon 9 exon 10 exon 11 exon 12 exon 13 exon 14 exon 15 exon 16 
exon 17 exon 18 exon 19 exon 20 
1F 
2F 
3F 
4F 
5F 
6F 
1R 
2R 
3R 
4R 
5R 
6R 
exon 21 
Table 15 – Exons of the GNPTAB transcript covered by each primer set 
and corresponding amplicon size. 
FCUP 
Development of an antisense-mediated exon skipping therapeutic strategy for Mucolipidosis II 
87 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As so, the amplification products with primer set 6 (Figure 23F), spanning exons 17 to 
21, were subsequently purified and sequenced. The obtained sequences were next 
compared with the GNPTAB transcript reference sequence ENST00000299314.11 retrieved 
from the Ensembl database to confirm the absence of any aberrant splicing surrounding the 
c.3503_3504delTC mutation and attest their availability for further experiments. Using the 
online software Clustal Omega, an almost complete match was observed between the two 
patients’ amplified sequences and the reference sequence, as well the presence of all 
expected exons without any alteration in their order or length. Aside from the expected 
c.3503_3504delTC mutation in exon 19 responsible for the ML II phenotype and a small 
number of single nucleotide polymorphisms (SNPs), the cDNA sequence of these two 
patients proved to be identical to the reference sequence and showed no evidence of any 
kind of aberrant splicing in this region of the gene. 
 
Overall, this analysis revealed a regular endogenous splicing pattern in the GNPTAB 
gene of the ML II patients, favoring the potential of these cell lines for use in the exon-
skipping experiments viewing the development of a novel therapeutic approach. 
 
 
 
 L      B      HC    P1     P2    L       B    HC    P1     P2 
 L        B      HC    P1     P2   L       B     HC    P1     P2 
 L        B     HC    P1     P2  L        B     HC    P1    P2 
A B 
C D 
E F 
Figure 23 – Agarose gel electrophoresis of amplification products of the GNPTAB transcript in patient 
and control fibroblasts. A: primer set 1; B: primer set 2; C: primer set 3; D: primer set 4; E: primer set 5; 
F: primer set 6. L: ladder; B: negative control (blank); HC: healthy control; P1: ML II Patient 1; P2: ML II 
Patient 2. 
~750bp 
~750bp 
C 
~750bp ~750bp 
~750bp 
~750bp 
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4.4. Exon-skipping antisense oligonucleotide in vitro 
therapeutic approach for patients affected by ML II 
 
Having confirmed the presence of the c.3503_3504delTC mutation in the two patient 
cells and the absence of any splicing alterations in the GNPTAB transcript, the fibroblasts 
were plated in 6-well plates and transfected with the four selected AOs at different 
concentrations in an attempt to induce the skipping of exon 19 from the final mRNA 
molecule. Following transfection, the cells were incubated for 24 hours after which total RNA 
was extracted for molecular analysis. The transcript region surrounding the target exon was 
then amplified through RT-PCR and the resultant products were separated through agarose 
gel electrophoresis, where full-length amplicons were expected to stretch for 734bp, while 
the shorter transcripts without exon 19 should only reach 566bp, allowing for a clear 
distinction between the two transcripts. Next, after this initial experiment with all four AOs at 
concentrations between 10nM and 100nM, the two most effective molecules were selected 
for additional testing and transfected into cells at higher doses (between 100nM and 500nM) 
to further study their effects on the splicing pattern of the GNPTAB gene. Lastly, when a 
possible pattern of exon-skipping was detected, the corresponding product was cut out from 
the gel and sequenced to confirm the exclusion of this exon from the final GNPTAB 
transcript. Below these experiments and their results are described in more detail. 
 
 
4.4.1. Evaluation of transfection efficiency with eGFP plasmid in control 
fibroblasts 
 
Before initiating the experiments of transfection with 
AOs, a plasmid containing the reporter gene eGFP was 
transfected into control fibroblasts in order to assess the 
efficiency of the Lipofectamine® 2000 transfection reagent. 
Following transfection and a 24 hours incubation period, cells 
were observed under a fluorescence microscope and green 
fluorescence was clearly visible in multiple cells (Figure 24), 
confirming the effectiveness of this reagent in transfecting 
these cultured fibroblasts and supporting its use for 
transfection of this kind of cells with the selected AOs. 
Figure 24 – Fluorescence microscopy 
images of healthy control fibroblasts 
transfected with eGFP. The strong 
green fluorescence visible in the cells 
confirms the efficiency of 
Lipofectamine® 2000 in transfecting 
cultured fibroblasts. 
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4.4.2. Splicing modulation of exon 19 with antisense oligonucleotides in healthy 
control and ML II patient fibroblasts 
 
4.4.2.1. Experiments in healthy control fibroblasts 
After confirming the effectiveness of the Lipofectamine® 2000 reagent in transfecting 
cultured fibroblasts and before testing the selected AOs in ML II fibroblasts cells, these 
molecules were transfected into fibroblasts of a healthy control. Here, the skipping of exon 19 
was also to be expected, since the target sequences for these AOs do not encompass the 
ML II causing mutation, which means they should have the same effect in both patient and 
control fibroblasts. Accordingly, all four oligonucleotides have induced some level of exon-
skipping in the control fibroblasts cells at the initially tested concentrations. As shown in 
Figure 25, an amplification product of around 550bp is present in most of the samples, 
matching the length of the GNPTAB transcript without exon 19 and indicating this exon has 
been successfully removed from the final mRNA molecule. 
 
 
 
 
H19A(-18+4) H19D(+12-9) 
L           B          Ø       10nM    25nM    50nM  100nM   10nM    25nM    50nM  100nM 
H19A(+45+64) H19A(+119+138) 
~750bp 
~550bp 
~750bp 
~550bp 
Figure 25 – Agarose gel electrophoresis of amplification products of the GNPTAB transcript 
(exons 17-21) in control fibroblasts after transfection with AOs. L: ladder; B: negative control 
(blank). Ø: control sample without AO. H19A(-18+4): directed to the 3’ss; H19D(+12-9): 
directed to the 5’ss; H19A(+45+64): directed to ESEs in the first half of exon 19; 
H19A(+119+138): directed to ESEs in the second half of exon 19.  
L             B       10nM     25nM     50nM    100nM    10nM     25nM     50nM   100nM 
heteroduplex 
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Out of the four AO tested, H19A(-18+4), which is directed to the 3’ss of exon 19, 
induced the skipping of this exon regardless of the concentration used, but showing higher 
efficiency at 25nM and 100nM. At 50nM, the shorter transcript appears with lower intensity 
than at 25nM but a third fragment is visible between the full-length mRNA and the shorter 
transcript without exon 19, which could be caused by partial skipping of the exon, an event 
that would also explain the lower amount of the transcript missing exon 19. Nonetheless, the 
amount of full-length transcript at the two highest concentrations, 50nM and 100nM, seems 
to be lower than at the two lowest doses, suggesting an increase in the ratio of transcript 
missing exon 19 versus full-length mRNA, which is one of the desired conditions to make this  
therapeutic strategy possible. Using the H19D(+12-9) AO, targeting the 5’ss, it is possible to 
observe a clear dose-dependent pattern concerning the amount of the shorter transcript, with 
a gradual increase in its levels from the lowest concentration of 10nM to 100nM. 
Among the two internal AOs, targeting ESEs within exon 19, the first molecule, 
H19A(+45+64), directed at the first half of the exon, shows some level of exon-skipping in all 
of the concentrations. However, at the lowest dose, 10nM, the visible product is longer than 
the expected transcript without exon 19, spanning over 600bp, which could suggest another 
case of partial skipping of the exon sequence. For the three other concentrations, the 
expected product is present, exhibiting an increase between 25nM and 50nM but decreasing 
once more at 100nM. Similar to H19A(-18+4), this decrease could be explained by the 
presence of a third fragment, with approximately the same length as the one present at 
10nM, possibly produced by the skipping of only part of exon 19. Furthermore, at 25nM and 
50nM, an amplification product around 500bp is tenuously visible, suggesting the possibility 
of the opposite situation, that is, the skipping of more than just exon 19, leading to an even 
shorter final transcript. As will be described in the next section, a similar product was 
observed in the experiments with the patient fibroblasts in which subsequent sequencing 
revealed a situation of skipping of both exon 19 and 20, which most likely also occurred in 
the control cells. At last, the H19A(+119+138) AO, directed at ESEs present in the second 
half of the exon, seems to achieve the skipping of exon 19 at all concentrations tested, 
displaying a clear dose-dependent response with a gradual increase in the amount of the 
shorter transcript across all four doses. Furthermore, at 10nM and 100nM, a third fragment is 
visible between the full-length mRNA and the shorter transcript missing exon 19, this time 
with around 700bp, and its sequencing revealed the existence of an heteroduplex between 
the full-length strand and the shorter strand without exon 19.  
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As the best results were obtained for the H19D(+12-9) and H19A(+119+138) AOs, 
higher concentrations (between 100nM and 500nM) of these molecules were further tested 
and both AOs were able to successfully induce the skipping of exon 19 at all of the tested 
conditions (Figure 26). 
 
 
 
 
 
 
 
 
 
 
 
 
At this range of AO concentration, H19D(+12-9) AO still appears to originate a dose-
dependent response, with gradual increases in the amount of the shorter transcript missing 
exon 19 as the concentrations tested also increase. The highest dose of 500nM was the 
exception here, with comparatively low levels of both transcripts when balanced against the 
other samples, possibly due to a very low amount of initial RNA for this amplification. 
Nonetheless, the amount of both transcripts obtained with this dose is nearly equivalent, 
reinforcing the positive results observed for the other four concentrations regarding the 
increase in the amount of shorter transcript to levels close to the full-length mRNA molecule.  
On the other hand, the amount of shorter transcript produced by action of the 
H19A(+119+138) AO only seemed to suffer a very small increase from 100nM to 200nM, 
with all the other concentrations, between 300nM and 500nM, exhibiting similar increasing 
levels of this transcript. Furthermore, the levels of full-length transcript in all of the tested 
concentrations appeared to be considerably lower than those of its shorter variant, which is 
most notorious at 500nM where the full-length mRNA is clearly reduced compared to the 
other conditions, leading to an increase in the ratio between the shorter transcript and the 
full-length variant and supporting the potential of this AO as an exon-skipping therapeutic 
agent for the treatment of ML II patients with mutations on exon 19. 
 
 
L            B          Ø      100nM  200nM  300nM  400nM  500nM  100nM  200nM  300nM  400nM  500nM 
H19D(+12-9) H19A(+119+138) 
~750bp 
~550bp heteroduplex 
Figure 26 – Agarose gel electrophoresis of amplification products of the GNPTAB transcript (exons 17-21) in 
control fibroblasts after transfection with AOs. L: ladder; B: negative control (blank). Ø: control sample without 
AO. H19D(+12-9): directed to the 5’ss; H19A(+119+138): directed to ESEs in the second half of exon 19.  
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4.4.2.2. Experiments in ML II Patient 1 fibroblasts  
For the first ML II patient, the electrophoresis gel seen in Figure 27 also revealed the 
existence of a shorter amplification product at about 550bp that most likely corresponds to 
the transcript missing exon 19 and appears to be present in the tests with all four AOs under 
analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The first AO, H19A(-18+4) binding the 3’ss region, seems to produce successful 
exon-skipping at the two highest concentrations, 50nM and 100nM, with a very faint band 
also visible at 25nM, which could suggest the presence of the shorter transcript at this dose, 
as well. Nonetheless, there is no clear increase in the amount of shorter transcript from 50nM 
to 100nM, preventing us from establishing a direct relation between the dosage used and the 
resultant level of exon-skipping. In the case of the second AO, H19D(+12-9) for the 5’ss 
region, the exon-skipping is visible at the three highest concentrations in a clear dose-
dependent pattern, with just 10nM, the lowest dose tested here, not revealing the presence 
of the shorter transcript. Furthermore, a fragment below 500bp also seems to be visible at 
25nM and 100nM, which is probably the result of the exclusion of exon 20 together with the 
target exon from the final transcript, as was already observed in the control fibroblasts. 
H19A(-18+4) H19D(+12-9) 
H19A(+45+64) H19A(+119+138) 
L          B         Ø      10nM   25nM   50nM  100nM  10nM   25nM   50nM  100nM 
L            B      10nM     25nM     50nM   100nM   10nM    25nM     50nM    100nM 
Figure 27 – Agarose gel electrophoresis of amplification products of the GNPTAB 
transcript (exons 17-21) in ML II Patient 1 fibroblasts after transfection with AOs. L: 
ladder; B: negative control (blank). Ø: control sample without AO. H19A(-18+4): directed 
to the 3’ss; H19D(+12-9): directed to the 5’ss; H19A(+45+64): directed to ESEs in the 
first half of exon 19; H19A(+119+138): directed to ESEs in the second half of exon 19.  
~750bp 
~550bp 
~750bp 
~550bp 
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Concerning the two exonic internal AOs, H19A(+45+64) for the first half of exon 19, 
induced the production of a shorter transcript at the concentrations of 25nM, 50nM and 
100nM, albeit in very low levels compared to the full-length transcript. Still, a distinct increase 
in the amount of the shorter mRNA is visible across the three doses, suggesting a dose-
dependent response to this treatment and that higher concentrations could offer even better 
exon-skipping levels. The AO for the second half of exon 19, H19A(+119+138), was 
considerably more successful than H19A(+45+64), with exon-skipping products in all 
concentrations tested and exhibiting a clear dose-dependent response. In fact, the highest 
tested dose, 100nM, revealed a considerable large amount of the shorter transcript, above 
what was observed for any of the other AOs, at any of the tested concentrations, nearly 
reaching the level of the full-length transcript and further supporting the efficiency of this AO 
in inducing the skipping of exon 19 from the GNPTAB transcript. 
 
In the same way, for the experiments with higher doses (between 100nM and 500nM) 
of H19D(+12-9) and H19A(+119+138), successful exon-skipping was achieved in all of the 
tested concentrations. A fragment below 500bp was also present in every sample, including 
the negative control without AO, which could result from the exclusion of the adjacent exon 
20 together with the target exon 19 from the GNPTAB transcript, as observed for the control 
fibroblasts and Patient 2, but could also be a naturally occurring alternative transcript only 
visible under certain conditions (Figure 28). 
 
 
 
In the case of the H19D(+12-9) AO for the 3’ss region, a clear dose-dependent 
pattern is observed, with a gradual increase in the amount of shorter transcript missing exon 
19 across the five doses, while the full-length transcript appears to remain unchanged. The 
H19A(+119+138) molecule, however, proved to be much more effective in these 
L          B           Ø     100nM  200nM  300nM  400nM 500nM 100nM  200nM  300nM  400nM 500nM 
H19D(+12-9) H19A(+119+138) 
~750bp 
~550bp heteroduplex 
Figure 28 – Agarose gel electrophoresis of amplification products of the GNPTAB transcript (exons 17-
21) in ML II Patient 1 fibroblasts after transfection with AOs. L: ladder; B: negative control (blank). Ø: 
control sample without AO. H19D(+12-9): directed to the 5’ss; H19A(+119+138): directed to ESEs in the 
second half of exon 19.   
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experiments, with strong production of the shorter fragment in all tested concentrations 
except 100nM, where the amount of this transcript is a bit lower. Additionally, the full-length 
transcript appears to be massively reduced in all samples, showing levels below those 
observed for the shorter variant without exon 19 in all of the conditions. Just as previously 
observed for this molecule in lower concentrations and other fibroblast cells, these results 
strongly support its capability of effectively inducing the skipping of exon 19, producing a 
shorter GNPTAB transcript, while also significantly reducing the amount of full-length 
transcript, ultimately inverting the ratio between these two molecules. 
 
 
4.4.2.3. Experiments in ML II Patient 2 fibroblasts 
In the case of Patient 2, the electrophoresis gel revealed the presence of some 
unspecific fragments, but still it was possible to identify the transcripts where the skipping of 
exon 19 was apparently successful. As seen in Figure 29, all four AOs exhibited positive 
results in all of the initially tested concentrations (10nM-100nM), with a dose-dependent 
response visible in most cases. Additionally, as seen in healthy control and Patient 1 
fibroblasts, a shorter fragment of about 500bp, resulting from the removal of both exon 19 
and 20, is also visible in most situations, albeit with much lower intensity than both the full-
length and the transcript without exon 19. 
 
 
 
 
H19A(-18+4) H19D(+12-9) 
     L          B          Ø      10nM    25nM   50nM   100nM  10nM    25nM   50nM   100nM 
~750bp 
~550bp 
H19A(+45+64) H19A(+119+138) 
L            B       10nM     25nM     50nM    100nM  10nM     25nM     50nM   100nM 
~750bp 
~550bp 
Figure 29 – Agarose gel electrophoresis of amplification products of the GNPTAB 
transcript (exons 17-21) in ML II Patient 2 fibroblasts after transfection with AOs. L: 
ladder; B: negative control (blank). Ø: control sample without AO. H19A(-18+4): directed 
to the 3’ss; H19D(+12-9): directed to the 5’ss; H19A(+45+64): directed to ESEs in the 
first half of exon 19; H19A(+119+138): directed to ESEs in the second half of exon 19.  
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In the specific case of the H19A(-18+4) AO binding the 3’ss region, there appears to 
be a decrease in the amount of the shorter fragment between the concentrations of 25nM 
and 50nM that can likely be attributed to the use of a smaller amount of initial RNA rather 
than to a reduced effect of the AO at this dosage. However, at the concentration of 100nM, 
the full-length transcript and the shorter variant seem to be present in equal amounts, 
proving the capacity of this molecule to induce exon 19 skipping. On the other hand, the 
H19D(+12-9) AO for the 5’ss, showcases a clear dose-dependent response, with regular 
increases in the amount of shorter transcript as the concentration of the therapeutic agent 
increases. Noticeably, the full-length mRNA is produced at a higher level than the transcript 
missing exon 19 and does not seem to undergo major changes across the four tested 
concentrations. 
As for the AOs targeting ESEs, the H19A(+45+64) molecule lead to a dose-
dependent response to the treatment, with the 10nM and 25nM concentrations generating 
very low levels of exon-skipping but producing a visible increase of the shorter transcript 
missing exon 19 at 50nM and 100nM. Moreover, a third fragment of about 600bp is visible at 
100nM, suggesting the possibility of a partial exon-skipping rather than the exclusion of the 
entire exon 19 from the final transcript. Lastly, in the case of the H19A(+119+138) AO, a 
dose-dependent response is once again visible with increasing amounts of the shorter 
transcript missing exon 19 accompanying the increasing AO concentrations. Simultaneously, 
the full-length transcript appears to be reduced at 25nM and 100nM, showing lower intensity 
than its shorter counterpart, which is particularly noticeable at the highest dose tested. In 
general, an increase in the ratio of transcript without exon 19 versus the full-length mRNA 
was observed, which once again supports the feasibility of the planned AO therapeutic 
approach. 
 
As for the experiments with the higher AO concentrations, both H19D(+12-9) and 
H19A(+119+138) successfully induced the skipping of exon 19 from the final GNPTAB 
transcript in all five concentrations tested (Figure 30). Once more, fragments of 
approximately 500bp and 700bp are also visible in the gel aside from the full-length and the 
truncated transcript, which most likely result from the skipping of exons 19 and 20 in the 
former and a partial skipping of exon 19 in the latter. 
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In the case of H19D(+12-9), there is an increase in the amount of transcript missing 
exon 19 between the concentrations of 100nM and 200nM, with the remaining doses 
showing strong and steady levels of this product. Additionally, with the exception of the 
lowest concentration, the shorter transcript levels are always superior to the full-length 
transcript, revealing an inversion in the ratio between these two transcript variants. 
Conversely, an increase in the levels of the transcript missing exon 19 is also visible between 
100nM and 200nM of the H19A(+119+138) AO, followed by solid levels of this transcript in all 
the other doses. Furthermore, as observed for Patient 1, the amount of full-length transcript 
is greatly reduced with this molecule, especially at the concentrations of 300nM and 500nM, 
where it is only visible as a faint band. Once more, this shows a massive increase in the ratio 
of shorter transcript versus full-length transcript, combining the successful skipping of exon 
19 from the GNPTAB transcript with a considerable reduction of the full-length mRNA. 
 
 
As a whole, these results confirm the ability of these AOs to induce the skipping of 
exon 19 from the GNPTAB transcript, therefore circumventing the ML II-causing mutation. 
Among the four molecules tested, H19A(+119+138) revealed to be the most promising, with 
great levels of transcript missing exon 19 while also reducing massively the amount of full-
length transcript, especially at the higher concentrations.  
 
 
 
 
H19D(+12-9) H19A(+119+138) 
   L            B           Ø      100nM  200nM   300nM  400nM  500nM  100nM  200nM  300nM   400nM  500nM 
~750bp 
~550bp 
heteroduplex 
Figure 30 – Agarose gel electrophoresis of amplification products of the GNPTAB transcript (exons 17-21) in 
ML II Patient 2 fibroblasts after transfection with AOs. L: ladder; B: negative control (blank). Ø: control sample 
without AO. H19D(+12-9): directed to the 5’ss; H19A(+119+138): directed to ESEs in the second half of exon 
19.  
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4.5. Quantification of the activity of several lysosomal 
enzymes in fibroblasts 
 
After obtaining preliminary data on the effectiveness of the therapeutic approach at 
RNA level, with the successful exclusion of exon 19 from the final GNPTAB transcript, 
quantification of some lysosomal enzymes within the cells was undertaken in order to 
indirectly evaluate the activity of GlcNAc-1-phosphotransferase following splicing modulation 
by AOs. To do that, healthy control and Patient 1 fibroblasts were transfected again with 
H19A(+119+138) – the most promising of the four AOs – at the concentration of 500nM and 
their pellets were collected for enzymatic assays to measure the amount of different 
enzymes before and after treatment.  
 
 
4.5.1. Enzyme levels prior to GNPTAB exon 19 splicing modulation with 
antisense oligonucleotides  
Prior to transfection with AOs, the amount of lysosomal hydrolases was measured 
through enzymatic assays to establish their endogenous levels in the different fibroblast 
cells. Aside from cells from the two ML II patients, two controls (HC1 and HC2) were also 
used, as well as cells from a Fabry patient (P3) and a MPS II (Hunter syndrome) patient (P4), 
in order to discriminate the pattern of ML II regarding the levels of multiple lysosomal 
enzymes. Results are shown on Table 16. 
 
 
 
 Enzyme activity (nmol/h/mg protein) 
 Cell lines 
Enzymes HC1 HC2 P1 (ML II) P2 (ML II) P3 (Fabry) P4 (MPS II) 
β-Glucosidase T+ 80,21 109,47 242,68 178,34 125,02 158,94 
β-Glucuronidase 78,42 77,44 13,39 29,64 ─ 233,98 
β-Galactosidase 366,01 450,06 5,84 6,64 519,96 410,69 
α-Galactosidase 17,16 14,31 2,19 0,32 17,20 28,62 
Arylsulfatase B (ARSB) 57,40 95,90 21,77 25,46 111,75 203,72 
Hexosaminidase T 35561,88 20973,83 6026,56 7112,47 ─ 43130,98 
α-Mannosidase 113,07 84,08 6,44 10,04 70,30 68,06 
 
Table 16 – Enzyme activity of lysosomal enzymes in fibroblasts of controls and LSDs patients. Due to small sample amount of 
the Fabry cell line, some enzymatic assays could not be performed for these fibroblasts. 
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Undoubtedly, both ML II patients present reduced levels of activity in all tested 
enzymes except β-glucosidase T+, whose activity in patients is actually higher than in the 
controls or the two other LSD patients. In reality, this is commonly observed in ML II patients, 
given that this enzyme is not transported through the M6P pathway and therefore is not 
affected by the absence of active GlcNAc-1-phosphotransferase (Reczek et al., 2007; Liou et 
al., 2014). Contrarily, the remaining six hydrolases, all rely on the M6P pathway for 
lysosomal targeting, which explains their reduced amounts in both ML II patients, with α-
galactosidase only showing residual activity in Patient 2. This is in line with results previously 
reported for ML II patients, who present lysosomal enzyme activity levels considerably below 
the normal range observed in control fibroblasts (Otomo et al., 2011; Alegra et al., 2014). 
Overall, the ML II fibroblast cells exhibit a unique pattern of general reduction in the 
levels of lysosomal enzymes, with the exception of β-glucosidase, which, in opposition, is 
quantitatively augmented. Thus, a clear distinction between ML II and other LSDs is feasible 
through the analysis of the activity of certain lysosomal enzymes, which is very important for 
both the diagnosis and the study of this lysosomal dysfunction. 
 
 
4.5.2. Enzyme levels following GNPTAB exon 19 splicing modulation with 
antisense oligonucleotides  
Following the initial assessment of enzyme activity, Patient 1 and control fibroblasts 
were transfected with 500nM of H19A(+119+138) AO and their enzyme activity was 
measured to assess whether the skipping of exon 19 could be associated with an increase in 
the levels of lysosomal hydrolases transported through the M6P-dependent pathway. Results 
are shown on Table 17. 
 
 
 Enzyme activity (nmol/h/mg protein) 
 
HC1 24 hours 
 
P1 (ML II) 24 hours 
 
P1 (ML II) 48 hours 
 
Enzymes - + - + - + 
β-Glucosidase T+ 143,89 155,17 1243,77 1148,11 320,66 410,58 
β-Glucuronidase 80,92 79,89 21,72 18,82 10,10 12,16 
β-Galactosidase 663,02 671,20 15,91 14,04 13,90 17,34 
α-Galactosidase 50,98 54,02 13,78 12,26 8,62 8,99 
Arylsulfatase B (ARSB) 121,66 125,60 52,41 58,37 44,08 47,26 
Hexosaminidase T 37774,81 53463,49 12588,29 11000,06 5818,07 6240,44 
α-Mannosidase 216,24 236,39 33,91 27,12 17,54 20,02 
Table 17 – Enzyme activity of lysosomal enzymes in fibroblasts of controls and ML II Patient 1 after transfection with the 
H19A(+119+138) AO. Plus sign (+) indicates the treatment with Lipofectamine 2000 + AO, while minus sign (-) indicates the 
treatment with just Lipofectamine 2000. 
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Comparatively with the results observed prior to AO transfection, the levels of the 
enzymes transported through the M6P-dependent pathway remains quite reduced compared 
to the control fibroblasts and very little change is observed in the presence of the AO despite 
RNA analysis confirming the successful skipping of exon 19. In fact, contrary to expectations, 
all enzymes in Patient 1 seem to present a slight decrease in their activity 24 hours after AO 
transfection, with the exception of ARSB which is slightly augmented in treated cells. On the 
other hand, 48 hours following transfection, enzyme activity appears to suffer a small 
increase in the patient fibroblasts for all enzymes tested, even if the results are still much 
lower than those observed for the healthy controls. It should be noted, however, that all 
mentioned variations appear to be too small to be significative and most probably cannot be 
considered relevant changes in the levels of lysosomal enzyme activities in the cells. 
 
As a whole, the results of the enzymatic assays suggest that the H19A(+119+138) 
AO was unable to produce significant changes in the levels of the lysosomal enzymes 
transported through the M6P-dependent pathway in ML II Patient 1 cells, despite effectively 
inducing the skipping of exon 19 from the final GNPTAB transcript. 
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Among the multiple mutations that can result in an ML II phenotype, the most frequent 
is c.3503_3504delTC, a dinucleotide deletion on exon 19 of the GNPTAB gene responsible 
for encoding the α/β-precursor peptide (Kudo et al., 2006; Coutinho et al., 2011). Broadly 
studied at our research group in the past, this mutation causes a frameshift in the transcript 
reading frame, as well as premature stop codon, and eventually leads to the production of a 
shorter inactive protein product (Plante et al., 2008). Included in the lost segment of the 
protein is the C-terminal arginine/isoleucine/arginine (RIR) motif, which together with the N-
terminal dileucine motif, is essential for the transport of the α/β-precursor from the 
endoplasmic reticulum to the Golgi apparatus where it can be cleaved into mature α and β 
subunits of the GlcNAc-1-phosphotransferase enzyme (Franke et al., 2013). Therefore, in ML 
II patients, this mutant peptide cannot exit the endoplasmic reticulum and consequently 
impairs its cleavage and the formation of mature α and β subunits, preventing GlcNAc-1-
phosphotransferase activity (De Pace et al., 2013). 
Considering the nature of this ML II causing mutation, the possibility of using AOs as 
therapeutic agents arose. Among the multiple mechanisms for which AOs can be employed, 
the most appropriate in this case was exon-skipping, which implies a strategy where AOs 
bind to specific splicing regulatory elements in the pre-mRNA in an attempt to exclude the 
target exon from the final transcript, therefore removing the disease causing mutation and 
restoring the reading frame (Hammond & Wood, 2011; Siva et al., 2014). This approach has 
previously been applied with encouraging results for the treatment of DMD, where AOs were 
used to induce the skipping of exon 51 (harboring the mutation) and produced an internally 
truncated but partially functional dystrophin protein, ameliorating the patients’ condition quite 
significantly (van Deutekom et al., 2007; Mendell et al., 2013). Similarly, we thought to use 
AOs in ML II patient fibroblasts to promote the exclusion of exon 19 from the final GNPTAB 
transcript, in order to circumvent the c.3503_3504delTC mutation and restore the reading 
frame, hoping to produce a truncated but functional α/β-precursor that could then be cleaved 
into mature α and β subunits and achieve GlcNAc-1-phosphotransferase activity. 
Considering the implications of removing a reasonable segment from the final protein 
product, our first step in this project was to analyze in silico the α/β-precursor peptide to 
ensure that the removal of exon 19 would actually produce an in-frame protein and that no 
important domains would be removed due to this exon-skipping approach. For that purpose, 
we performed a thorough analysis of this peptide, using multiple bioinformatic tools and 
softwares. The alignment of the amino acid sequence of the GNPTAB protein product minus 
exon 19 with the normal GNPTAB protein product showed that removing exon 19 indeed 
produced an in-frame protein, 56 amino acids shorter than the regular protein product, but 
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with the amino acid sequence following the excluded region presenting a complete match to 
the normal α/β-precursor peptide. When the amino acid sequence encoded by exon 19 was 
aligned with from multiple animal species, a great level of conservation was detected 
between the sequences, with just small discrepancies in the sequences from mouse and 
zebrafish. However, while important protein domains are usually conserved across species, 
the opposite is not always true, with several regions presenting high levels of conservation 
without any apparent function.  
Acknowledging this, protein domains were predicted for the GNPTAB protein product 
to confirm the absence of essential elements within the region encoded by exon 19 that 
would naturally be excluded by the planned exon-skipping approach. Predictions obtained 
from three different databases all confirmed the presence of several domains previously 
described for this protein product: the stealth domain, spread across four regions, two Notch 
repeats and a DMAP domain (Qian et al., 2015; van Meel et al., 2016). The Notch repeats 
are characteristic of Notch receptor family members and regulate the cleavage of the Notch 
receptor, preventing its activation in the absence of a proper ligand (Sanchez-Irizarry et al., 
2004), while the DMAP domain functions as an interaction domain between proteins and is 
responsible for the selective binding of this enzyme to lysosomal hydrolases (Qian et al., 
2013). Together, these domains are essential for the recognition and binding of lysosomal 
enzymes to GlcNAc-1-phosphotransferase, with mutants on either of these locations 
maintaining the catalytic activity of this enzyme and its location in the Golgi apparatus but 
losing the ability to phosphorylate any lysosomal hydrolases (van Meel et al., 2016). On the 
other hand, the stealth domain is highly conserved in bacteria and metazoans and appears 
to play an important role in the synthesis of extracellular polysaccharides and evasion of 
detection by the host’s immune system, providing great advantage to pathogenic bacteria 
(Sperisen et al., 2005). In the GlcNAc-1-phosphotransferase enzyme, however, this domain 
has been shown to harbor the catalytic site, as mutations in these regions have severely 
reduced the activity of the enzyme, without affecting its Golgi localization and proteolytic 
cleavage (Qian et al., 2015). Given this, the presence of stealth domain CR4 within the 
amino acid sequence encoded by exon 19 could appeared to be quite problematic, since the 
removal of this domain from the final protein product could lead to a decrease or even 
absence of GlcNAc-1-phosphotransferase catalytic activity, rendering this therapeutic 
approach unfit for the treatment of ML II. Still, since only one out of the four stealth domains 
would be excluded, we hypothesized that some residual activity could still be present after 
skipping of exon 19. It is, therefore, imperative that enzyme activity is carefully analyzed 
following the application of this innovative therapy in order to ensure it produces a functional 
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enzyme, even if only partially, rather than a Golgi-located but inactive protein, which would 
do very little to ameliorate the phenotype of this disorder. Aside from those domains, the γ-
subunit binding (GB) region has also been identified in a previously uncharacterized region of 
the α-subunit between amino acid positions 535 and 698 (De Pace et al., 2015) but was not 
predicted by any of the three consulted databases. More recently, Velho and colleagues 
were able to distinguish two subdomains within this region – GB1 (aa 535-588) and GB3 (aa 
645-698) – which play an essential role in the interaction between the α-subunits and the γ-
subunits, as indicates the observation that the simultaneous deletion of both subdomains 
leads to a complete loss of interaction between the subunits, while the deletion of each of 
them alone causes a reduction in protein interaction (Velho et al., 2016). While these 
subdomains do not interfere directly with our target region, the very recent identification of 
this γ-subunit binding region testifies the constant progress on research and knowledge 
about this enzyme, as well as multiple others, and reinforces the necessity for permanent 
updates of online databases in order to provide users with the most recent discoveries and 
correct information in the field.  
Regarding protein glycosilation, despite the fact that the α/β-precursor is a highly N-
glycosylated peptide (Velho et al., 2016), bioinformatic predictions did not indicate any sites 
with strong glycosylation potential within the amino acids encoded by exon 19, which is 
consistent with information previously published in the literature (Kollmann et al., 2010). 
Thus, it is unlikely that the removal of exon 19 from the final GNPTAB transcript would have 
some impact on the glycosylation of this protein product, since all of the glycosylation sites 
would remain intact and available for this post-translational modification. In summary, 
according to the combined bioinformatic analyses, the main contrariety of correcting the 
c.3503_3504delTC mutation through an exon-skipping approach was that a considerable 
portion of the stealth domain CR4 would be removed from the α/β-precursor, which could 
severely impact the catalytic activity of the GlcNAc-1-phosphotransferase enzyme. 
Nonetheless, the fact of such impairment being a mere prediction obtained from bioinformatic 
tools, having  not yet been experimentally confirmed, together with the remaining 
bioinformatic indications being quite encouraging, prompted us to further continue our work 
in the development of this innovative therapeutic approach for the treatment of ML II. 
Bioinformatic tools were then used to design AOs and select the most appropriate 
targets to induce the skipping of exon 19 of the GNPTAB gene. For that purpose, the 
acceptor and donor splice sites of the exon were scored according to their strength, that is, 
their similarity to the consensus sequence, to verify whether they could be useful targets for 
AO binding. Two distinct bioinformatic tools provided concordant scores, with the 3’ss 
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consistently outscoring the 5’ss on both platforms, which suggests the presence of a very 
strong acceptor site on exon 19, expected to play a crucial role in the splicing reaction. In 
light of these findings, this location came forward as a very promising target for AOs, as the 
blocking of the 3’ss alone could prevent the recognition of the exon by the splicing machinery 
and result in its exclusion from the final transcript. Additionally, the presence of enhancers 
within exon 19 and its flanking intronic regions (50bp) was predicted with bioinformatic tools 
as these could equally be potential targets for AOs. In this case, results revealed the 
presence of several enhancers across the sequence of the exon, with a dense cluster around 
the 5’ss. However, the highest scoring enhancers were not present in this cluster, but rather 
in the first half of the exon and surrounding the 3’ss, suggesting this region could also be 
target by AOs for the purpose of inducing the skipping of exon 19. In fact, previous studies 
associated with exon-skipping in the dystrophin gene indicate a tendency for AOs targeting 
the acceptor site or enhancers present in the first half of the exon to show higher levels of 
efficiency than those targeting other locations (Wilton et al., 2007; Fletcher et al., 2012). 
Therefore, we decided to also explore the design of AOs in this region to verify whether the 
efficient outcomes would hold true for the GNPTAB gene and if AOs targeting these positions 
would successfully promote the exclusion of exon 19 from the final transcript. At the end, four 
AOs were designed: one for each splice site and two for exonic internal regions with high 
density of predicted enhancers, expecting that at least one of these molecules would 
efficiently induce the skipping of exon 19 of the GNPTAB gene. 
Moving next to the experimental framework, fibroblast cells from two distinct ML II 
patients were cultured and characterized to confirm the presence of the c.3503_3504delTC 
mutation, while their endogenous splicing pattern was also assessed to ensure that no 
splicing abnormalities were present in these cells prior to transfection with AOs. As expected, 
the results from these two molecular analyses confirmed the presence of the 
c.3503_3504delTC mutation in the patient fibroblasts, as well as a regular endogenous 
splicing pattern, proving that these cells are suitable for use in the planned exon-skipping 
experiments.  
Since the c.3503_3504delTC mutation and an unaltered splicing pattern were 
successfully confirmed in the patient fibroblasts, we moved on to their transfection with the 
selected AOs. Overall, all four AOs achieved successful skipping of exon 19, at least to some 
extent. However, contrary to what has previously been published (Arechavala-Gomeza et al., 
2007;  Harding et al., 2007; Wilton et al., 2007), the most effective molecules were not the 
AOs targeting the acceptor splice site or the first half of the target exon. In fact, among the 
four molecules tested, the AOs directed at the donor splice site, H19D(+12-9), and the 
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second half of the exon, H19A(+119+138), managed to accomplish higher levels of exon-
skipping and displayed a very consistent dose-dependent response, with a gradual increase 
in the amount of the shorter transcript across the four tested concentrations. 
In the case of H19D(+12-9) AO, the efficiency of exon-skipping can be explained by 
the crucial role the donor splice site plays in the spliceosome assembly, since its recognition 
and binding by U1 snRNP represents the first step in the complex cellular process of splicing 
(Chen & Manley, 2009; De Conti et al., 2013). In that sense, the blocking of this location 
alone by the H19D(+12-9) AO might have inhibited the assembly of the spliceosome complex 
in this region and consequently lead to the exclusion of exon 19 from the final GNPTAB 
transcript in the treated cells. Furthermore, the 5’ss of this particular exon is surrounded by a 
considerably high number of enhancer elements, both within the exon and in the intronic 
sequence, and these are equally blocked by H19D(+12-9), which greatly diminishes their 
action and ultimately prevents the inclusion of exon 19 in the final mRNA. 
Another important factor is the secondary RNA structure of the target region, which 
can greatly influence the binding and efficiency of AOs. As described by Aartsma-Rus 
(Aartsma-Rus, 2012), immediately following transcription, the pre-mRNAs form secondary 
structures, leaving some sequences strongly bound to each other in a closed structure, while 
others originate loops, where they are in a more accessible and open structure. Considering 
this, AOs must have as target a balanced structure, partially open and partially closed, in 
order to bind successfully to it and significantly alter the RNA secondary structure to induce 
the intended splicing modulation. Otherwise, if the target structure is too closed, the AO will 
probably fail to bind to the sequence, whereas if the structure is completely open, the AO 
might bind to the sequence but most likely will not alter the RNA structure in a substantial 
manner, producing little to no effect (Aartsma-Rus, 2012). The results observed here could 
also reflect these differences in target structure, with the binding of AOs to some locations 
showing higher levels of exon-skipping and more consistent outcomes probably due to 
targeting a more favorable RNA structure, whereas other RNA segments may present 
excessively open or closed structures, hindering the action of AOs.  
Aside from these factors associated with RNA structure and AO location, the 
transfection reagent selected for the experiment may also play a significant role in its 
efficiency, leading to different levels of exon-skipping. In fact, when the skipping of exon 19 
from the GNPTAB transcript was experimentally tested using Lipofectamine LTX no exon-
skipping was observed in any of the conditions tested (data not shown). However, when 
Lipofectamine 2000 was used for the transfection, exon-skipping was successfully achieved 
in most of the conditions and a shorter transcript without the target exon was clearly visible in 
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most of the samples. It is, therefore, important to weight the choice of the transfection 
reagent to be used in this sort of experiments and test different alternatives in order to attain 
a more accurate perception on the efficiency of specific AOs, and consequently on the 
feasibility of this technique. 
Additionally, besides the full-length GNPTAB transcript and its shorter variant missing 
exon 19, some samples also revealed the presence of other amplification products between 
these two fragments. As previously observed in studies carrying out the skipping of exons in 
DMD (van Deutekom et al., 2007; Kinali et al., 2009, Adkin et al., 2012), intermediate 
fragments appear with relative frequency in the course of exon-skipping techniques. 
Possibly, they can result from a partial skipping of the target exon sequence, producing a 
transcript shorter than its endogenous variant but still longer than the desired molecule, 
which in this work was a sequence missing the full exon 19. In turn, an even shorter 
transcript, spanning about 500bp, was visible in some of the samples, including from 
transfection controls without any AOs, and its sequencing revealed the opposite situation, 
with both exon 19 and 20 absent in the final GNPTAB transcript. While the unexpected 
splicing of extra exons has also been reported as a common side event in exon-skipping 
procedures (Adkin et al., 2012; Fletcher et al., 2012), here the detection of such a product in 
the control sample is quite intriguing since no AO was administered to justify the splicing 
alteration. Still, this transcript could be a minor endogenous alternative splicing product only 
observed under certain experimental conditions. Although these amplification products do 
not compromise the success of this exon-skipping approach, they serve as a reminder that 
this sort of technique still requires strong refinement before it can proceed to in vivo 
experiments in order to prevent the possibility of adverse secondary effects.  
Given the positive results observed for the H19A(+119+138) and H19D(+12-9) AOs, 
targeting the ESEs within the second half of the exon and the donor splice site, respectively, 
these two molecules were selected for further evaluation with higher concentrations. As 
observed at lower AO concentrations, both molecules induced a successful skipping of exon 
19 in patient and control fibroblasts. However, while H19D(+12-9) revealed a clear dose-
dependent response and a gradual increase in the amount of shorter transcript missing the 
target exon, H19A(+119+138) did not, instead resulting in stable but solid levels of shorter 
transcript and only small amounts of the full-length mRNA. This was especially clear in the 
patient fibroblasts where the levels of shorter transcript far surpassed those observed for the 
full-length mRNA, effectively inverting the ratio between these two variants of the GNPTAB 
gene. Once again, these results oppose the data previously reported (Arechavala-Gomeza et 
al., 2007;  Harding et al., 2007; Wilton et al., 2007), according to which the most effective 
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AOs are those directed to the acceptor splice site or the first half of the target exon. Here we 
observed that, despite blocking an essential location for the assembly of the spliceosome, 
the H19D(+12-9) AO turned out to be slightly less efficient than H19A(+119+138), the one 
binding to an internal location in the second half of the exon, without particularly strong 
ESEs, which, based on the bioinformatic predictions would make it the least likely of the two 
AOs to induce successful exon-skipping. Actually, H19A(+119+138) showed the best results 
and appears to be the most promising AO among the four tested, strongly inducing exon-
skipping and leading to the production of very satisfactory levels of GNPTAB transcript 
missing exon 19. Additionally, it also effectively reduced the full-length out-of-frame mRNA to 
levels below those observed for its shorter variant, demonstrating the potential of this 
molecule as a future innovative therapeutic agent for ML II. 
At last, the impact of this therapeutic approach at protein level was assessed 
indirectly by quantification of lysosomal enzymes and their activity. Since in ML II patients 
harboring the c.3503_3504delTC mutation, GlcNAc-1-phosphotransferase activity is almost 
totally absent, the removal of exon 19 from the final GNPTAB transcript was expected to 
restore, at least to some degree, the activity of the enzyme, to attain an improvement of 
lysosomal trafficking and reduction of excreted lysosomal enzymes. Unfortunately, in patient 
fibroblasts transfected once again with the H19A(+119+138) AO for 24 and 48 hours, no 
significant change in activity in a number of lysosomal hydrolases was detected, which was a 
sign that no GlcNAc-1-phosphotransferase activity had been restored. Nonetheless, minor 
increases in enzyme activity were observed at 48 hours, suggesting this period of incubation 
was slightly more effective in improving GlcNAc-1-phosphotransferase activity and that 
extending the experiment for a longer period of time could produce overall better results.  
Soon in the work, we anticipated that, given the role of stealth domains for the 
catalytic activity of GlcNAc-1-phosphotransferase (Qian et al., 2015), the presence of a 
considerable portion of stealth domain CR4 within the amino acid sequence encoded by 
exon 19 could represent a serious issue for the planned therapeutic approach. However, the 
presence of three other stealth domains in the α/β-precursor allowed us to hypothesize that 
enzyme activity would not be totally lost after removing the CR4 domain. Also, only two 
missense mutations are listed in The Human Gene Mutation Database for this domain, one 
associated with a very mild ML III phenotype (Otomo et al., 2009) and the other associated 
with a case of stuttering (Kang et al., 2010), while in other locations of this protein missense 
mutations have been linked to a severe ML II phenotype (Otomo et al., 2009; Zarghooni et 
al., 2009; Qian et al., 2015). Therefore, based on these first results it is not possible to 
conclude for sure that the activity of the GlcNAc-1-phosphotransferase was not partially 
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recovered, since we only used indirect methods for checking its status. In fact, GlcNAc-1-
phosphotransferase levels are much more reduced in ML II patients than in ML III patients 
and well correlated with the more severe phenotype that is observed in ML II patients. 
However, these two ML forms cannot be distinguished through the indirect quantification of 
the lysosomal enzyme activities since their levels are similar in both diseases, which 
supports the need for a direct evaluation of GlcNAc-1-phosphotransferase activity.    
As corollary, while this work showed encouraging results at RNA level, further 
research is still needed to obtain a better assessment of the activity of the resultant protein 
product. As explained in previous chapters, direct measurement of GlcNAc-1-
phosphotransferase activity is not routinely used for diagnosis because it requires a 
cumbersome method involving the radioactive substrate [32P]UDP-GlcNAc only feasible to be 
carried out in specialized facilities (Reitman & Kornfeld, 1981a), with most routine 
evaluations performed through indirect measurements. In this research project, however, 
direct evaluation should necessarily be conducted, because it is much more sensitive than 
the indirect alternative, constituting the best means to verify whether the developed exon-
skipping strategy manages to restore some level of protein activity, despite the absence of 
the 56 amino acids encoded by exon 19. In addition, expression analysis of a mutant 
GNPTAB construct without exon 19 by Western blotting and immunofluorescence 
microscopy could help verify whether the α/β-precursor is retained in the endoplasmic 
reticulum or is correctly transported to the Golgi apparatus and proteolytically processed, 
supporting or not the feasibility of this approach. 
As previously reported (Steet et al., 2005), patients diagnosed with the milder ML III 
disorder also exhibit levels of GlcNAc-1-phosphotransferase activity below the normal range 
(2-20%) but their symptoms and overall phenotype are considerably more favorable than in 
ML II patients. One patient in particular, carrying a missense mutation within the region 
encoded by exon 19 of the GNPTAB gene, exhibited very low levels of GlcNAc-1-
phosphotransferase activity (<2%) but still presented with a very mild ML III phenotype 
(Otomo et al., 2009; Qian et al., 2015). Expectedly, an increase in the levels of enzyme 
activity to about 6-10% of normal would probably allow for a serious improvement in the 
condition of these patients and extend their life expectancy (Steet et al., 2005). Moreover, 
past studies have reported on asymptomatic individuals with very reduced levels of enzyme 
activity for other lysosomal enzymes (Leinekugel et al., 1992), as well as for enzymes 
associated with cystic fibrosis (Rowntree & Harris, 2003). More recently, an heterozygous ML 
III carrier was demonstrated to only exhibit 36,2% of normal GlcNAc-1-phosphotransferase 
activity despite presenting with a normal clinical phenotype (Cathey et al., 2010). These 
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findings reinforce that it is possible to achieve a normal asymptomatic phenotype with levels 
of enzyme activity considerably lower than those observed in the normal range and that even 
small increases in enzyme activity can have a major impact in ameliorating the symptoms 
associated with these disorders. 
 Nonetheless, further research and investment is still needed in the field of ML II for 
the development and implementation of innovative therapeutic strategies, opening the way to 
offer one day personalized treatments to patients that can ultimately improve their overall 
quality of life. 
 
  
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 6 
Conclusion and Future Perspectives 
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In recent years, as new information on RNA biology and chemistry arose, this 
molecule became one of the most promising targets for therapeutic intervention in multiple 
diseases associated with genetic mutations present in the transcriptome. Unlike other forms 
of therapy focused on ameliorating the symptoms of a disorder, RNA therapeutics act directly 
upon the disease causing mutation, allowing for a very precise and specific treatment with 
reduced secondary effects. One of the most notorious examples of the utility of RNA-based 
therapies is the recent developments in the field of DMD, where AOs have successfully been 
used for the skipping of specific exons and have been approved for clinical use since the end 
of last year after years of intensive research (Aartsma-Rus & Krieg, 2017). 
Considering this and other achievements in disorders where AOs were approved for 
clinical use (Crooke & Geary, 2013; Chery & Näär, 2016; Ottesen, 2017), this project set out 
to develop a similar exon-skipping strategy for the treatment of patients harboring the 
c.3503_3504delTC mutation responsible for ML II. After testing in vitro different AOs and 
concentrations through transfection, we can safely affirm that all four AOs tested were able to 
induce the skipping of exon 19 to some extent, confirming that the exclusion of this sequence 
from the GNPTAB transcript is indeed feasible through this sort of technique. Among the 
selected AOs, H19A(+119+138), directed at a region of ESEs within the second half of the 
target exon, clearly stood out as the most successful, having produced a considerable 
amount of the shorter transcript missing exon 19, even at relatively low dosage. At the same 
time, this AO also promoted a significant reduction in the amount of full-length mRNA in the 
treated fibroblast cells, consequently increasing the ratio between the shorter transcript 
variant and the full-length molecule. Given the ultimate goal of this therapeutic approach – 
the complete replacement of the natural occurring GNPTAB transcript harboring the 
c.3503_3504delTC mutation with the shorter mRNA missing exon 19 resultant from this 
exon-skipping strategy –, this AO appears quite promising and should therefore be further 
explored as a potential treatment for ML II patients carrying exon 19 mutations. 
Unfortunately, these encouraging results did not replicate at protein level, as the assessment 
of enzyme activity for several lysosomal hydrolases following transfection with 
H19A(+119+138) revealed very small changes when compared to untreated fibroblasts. 
However, considering these are only indirect measurements of GlcNAc-1-
phosphotransferase activity, for the moment it cannot be definitely excluded that some level 
of enzyme activity has been restored, since that can only be confirmed with direct assays.  
Nonetheless, the mRNA results are very encouraging and further research should be 
conducted regarding this exon-skipping strategy. 
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On grounds of these results, the next logical step would be to thoroughly study the 
expression levels of both GNPTAB transcripts through Real-Time PCR techniques in order to 
measure accurately the action of the AOs used. Additionally, the protein product resultant 
from the skipping of exon 19 should also be carefully analyzed. As previously noted (Velho et 
al., 2015; De Pace et al., 2013; Franke et al., 2013; van Meel et al., 2016), it is crucial to 
study the effects of such an impactful alteration of the transcript at protein level, using 
Western Blot techniques to compare the expression patterns of both protein variants (full-
length and artificially truncated), as well as verify the length of the α/β-precursor following the 
exclusion of exon 19 and ultimately confirm the successful cleavage of the α and β subunits, 
allowing for the assembly of an active GlcNAc-1-phosphotransferase enzyme. 
Additionally, experiments for quantification of lysosomal enzyme activity should be 
carried out for a longer period of time and using higher AO concentrations, and enzyme 
levels should also be measured on culture media since enzymes that fail to reach the 
lysosome are subsequently secreted to the extracellular milieu (Kornfeld & Sly, 2001; 
Braulke et al., 2008). Furthermore, GlcNAc-1-phosphotransferase activity should also be 
assessed directly to accurately determine its level of restoration. The use of radioactive 
[32P]UDP-GlcNAc as the donor substrate together with the phosphate acceptor α-
methylmannoside (α-MM) as first described by Reitman and Kornfeld allows for a direct 
measurement of GlcNAc-1-phosphotransferase activity (Reitman & Kornfeld, 1981a), which 
could provide very important information regarding the effects of this therapeutic approach at 
enzyme level (Steet et al., 2005; Kudo et al., 2006; Qian et al., 2010; Velho et al., 2015). In 
alternative, given the role of this enzyme in marking lysosomal enzymes with M6P, its activity 
could also be estimated through the immunoprecipitation of M6P-containing proteins using a 
M6P-specific antibody in order to verify if any changes in the amount of M6P-containing 
proteins are visible following AO transfection (Muller-Loennies et al., 2010). 
Lastly, the location of GlcNAc-1-phosphotransferase is also an important point to 
address in the scope of this therapeutic approach, since the endogenous α/β-precursor in ML 
II is retained in the endoplasmic reticulum and is unable to progress to the Golgi apparatus, 
where the cleavage of the α and β subunits occurs and the assembly of a functional GlcNAc-
1-phosphotransferase takes place (De Pace et al., 2013; Franke et al., 2013). In that sense, 
it would be interesting to examine the subcellular localization of both the α/β-precursor and 
the GlcNAc-1-phosphotransferase enzyme, using specific antibodies and fluorescence 
microscopy, in order to assess whether the altered protein product can successfully reach 
the Golgi apparatus. Similarly, the same methods could also be used to identify the 
subcellular localization of some lysosomal enzymes to confirm their presence within the 
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lysosomal compartment and not in the extracellular milieu, as commonly happens in ML II 
patients (De Pace et al., 2013; Franke et al., 2013; Velho et al., 2015; van Meel et al., 2016). 
The success of this therapeutic approach also depends of other major challenges, 
such as the successful delivery of this AO to the target tissues, which is still one of the most 
complex issues in the field of RNA therapeutics. Given the difficulty of cellular uptake for 
naked AOs, several delivery mechanisms have been tested in an attempt to improve the 
success of this process and increase the levels of AO inside the cell. However, some of the 
agents used, like cell-penetrating peptides, cationic lipids or polymers, still present some 
risks and associated toxicity, requiring careful testing and refinement before they can be 
considered for clinical use (Amantana et al., 2007; Moreno & Pêgo, 2014; Gurav & 
Srinivasan, 2017). Furthermore, viral vectors, which have previously been used for the 
incorporation and delivery of AOs due to their natural ability to penetrate cells, can also face 
some obstacles when used in vivo because they can activate the host’s immune system with 
the consequent production of specific antibodies that neutralize the action of these viral 
vectors in future systemic injections (Douglas & Wood, 2011; Imbert et al., 2017). 
Additionally, even in the presence of delivery mechanisms, most AOs fail to reach the central 
nervous system when administered peripherally due to their inability to cross the blood-brain 
barrier (Chery & Näär, 2016). Considering most of the disorders targeted by AO therapies, 
including ML II, present severe neurological symptoms, the nervous system must be an 
essential focus for the treatment with AOs and alternative delivery methods that ensure 
efficient distribution of these agents into the brain must be developed and refined. 
Finally, before reaching widespread medical use, AOs must face one last hurdle: 
clinical approval and regulation by drug administrations and medicine agencies. While all 
medicines go through this phase of the drug development pipeline before entering the 
market, the process can be quite more complex for AOs, especially those targeting rare 
diseases. Not only is the number of patients with these disorders obviously reduced, those 
who carry a specific mutation feasible to be treated with the same AO are an even smaller 
group, making it very difficult to conduct robust clinical trials (Douglas & Wood, 2011). Taking 
this into account, the scientific community has been working towards considering AOs as a 
single drug class in order to facilitate their approval and ultimately accelerate the progress in 
the development of new therapies (Hammond & Wood, 2011). This would give a completely 
different opportunity to these drugs, opening the possibility to provide patients, even those 
with private mutations, with the necessary AO treatment for their disorders, bringing 
everyone closer to the prospects of truly personalized medicine. 
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Overall, this study was pioneer in the development of antisense-mediated exon-
skipping strategies for the treatment of ML II, achieving encouraging results and reinforcing 
the role of AOs as very promising therapeutic agents for this and other severe disorders. 
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Background 
Mucolipidosis type II is one of the most severe LSDs and is caused by the deficiency 
of GlcNAc-1-phosphotransferase activity, a hexameric enzyme which plays an essential role 
in the trafficking of lysosomal hydrolases to the lysosomes (Kornfeld & Sly, 2001). Despite 
the severity of this disorder, which often leads to death within the first decade of life, 
therapeutic approaches are scarce and there is no definitive cure currently available, with 
most treatments simply tackling the symptoms and not the genetic origin of ML II. Among the 
multiple mutations that can result in an ML II phenotype, the most frequent is 
c.3503_3504delTC, a dinucleotide deletion on exon 19 of the GNPTAB gene. In recent 
years, the RNA molecule became one of the most promising targets for therapeutic 
intervention in multiple diseases associated with genetic mutations. Some of the most 
notorious examples of this utility of the RNA molecule as a target for therapy are the recent 
developments in the field of Duchenne Muscular Dystrophy (DMD), where antisense 
oligonucleotides (AOs) have successfully been used for the skipping of specific exons and 
have been approved for clinical use (Aartsma-Rus & Krieg, 2017). Acknowledging this, the 
present study intends to design and develop an RNA-based therapeutic agent through the 
use of antisense oligonucleotides capable of inducing the skipping of exon 19 of the 
GNPTAB gene and consequently circumvent the effects the most common ML II causal 
mutation. 
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Methodology 
1. Several bioinformatics tools were used to explore thoroughly i) exon 19 of the 
GNPTAB gene where is located the c.3503_3504delTC mutation, the target molecular defect 
in this study from the therapeutic perspective; ii) its flanking intronic regions and iii) the final 
protein product. 
 
2. Skin fibroblasts of two distinct patients with an established ML II diagnosis, both 
homozygous for the c.3503_3504delTC mutation, were obtained from the Cell Line and DNA 
Biobank from Patients Affected by Genetic Diseases (Istituto Giannina Gaslini, Genova, 
Italy), while control cells were retrieved from healthy donors. 
 
3. Design and selection of the most promising AOs were done using the guidelines 
and parameters previously described by Aartsma-Rus, 2012. 
 
4. The fibroblasts were plated in P6 plates and transfected using Lipofectamine 2000 
with the four selected antisense oligonucleotides at different concentrations. Fibroblasts from 
healthy individuals were also transfected as control experiments. 
 
5. The effectiveness of this therapeutic approach regarding the restoration of GlcNAc-
1-phosphotransferase activity was assessed indirectly through the quantification of some 
lysosomal enzymes. 
 
 
Results 
1. Sequence alignments of GNPTAB protein products 
First, we aligned the amino acid sequence of the GNPTAB protein product minus 
exon 19 with the normal GNPTAB protein product and verified that removing exon 19 indeed 
produced an in-frame protein, 56 amino acids shorter than the regular protein product. 
 
2. Prediction of protein domains within the GNPTAB protein product 
Predictions obtained from three different databases (Pfam 30.0, UniProt and InterPro) 
confirmed the presence of several domains previously described for this protein product: the 
stealth domain, spread across four regions, two Notch repeats and a DMAP domain (Qian et 
al., 2015; Velho et al., 2015; van Meel et al., 2016). 
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3. Splicing modulation of GNPTAB exon 19 with antisense oligonucleotides in 
healthy control and ML II patient fibroblasts 
After testing different concentrations, we can safely affirm that all four 
oligonucleotides tested were able to induce the skipping of this target exon to some extent. 
Among the selected AOs, H19A(+119+138), directed at a region of exonic enhancer 
elements within the second half of the target exon, clearly stood out as the most successful 
of the four. 
 
4. Quantification of the activity of several lysosomal enzymes in fibroblasts 
The assessment of enzyme activity for several lysosomal hydrolases following 
transfection with H19A(+119+138) aimed at the skipping of exon 19 of the GNPTAB gene 
revealed very small changes when compared to untreated fibroblasts. 
 
Conclusion 
Given the ultimate goal of this therapeutic approach – replacement of the natural 
occurring GNPTAB transcript harboring the c.3503_3504delTC mutation with the shorter 
mRNA missing exon 19 resultant from this exon-skipping strategy – , this oligonucleotide 
appears quite promising in this pursuit and should therefore be further explored. However, 
results showed little to no change in enzyme activity following transfection with AOs. Given 
the role of stealth domains for the catalytic activity of GlcNAc-1-phosphotransferase, the 
presence of a portion of stealth domain CR4 within the amino acid sequence encoded by 
exon 19 was expected to be an issue for this therapeutic approach. However, the presence 
of three other stealth domains in the α/β-precursor could allow for some enzyme activity after 
removing the CR4 domain. Indeed, based on these first results, it is not possible to conclude 
for sure that the activity of GlcNAc-1-phosphotransferase was not partially recovered, once 
we are using an indirect way of checking its status. In fact, ML II cannot be distinguished 
from ML III on the basis of residual lysosomal enzymes activities as they are similar in both 
disorders even though the activity of the GlcNAc-1-phosphotransferase is much more 
reduced in ML II and the clinical symptoms are much milder in ML III patients. In summary, 
while this work showed encouraging results at RNA level, further research is still needed 
regarding the activity of the resultant protein product. 
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